================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------
FORM 10-K
(Mark One)
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended August 31, 1998
[_] TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ___________ to ___________.
Commission file number:0-21884
REXALL SUNDOWN, INC.
(Exact name of Registrant as specified in its charter)
Florida 59-1688986
(State or other jurisdiction (I.R.S. Employer
of incorporation or organization) Identification No.)
6111 Broken Sound Parkway, NW
Boca Raton, Florida 33487
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code:
(561) 241-9400
------------------------
Securities registered pursuant to Section 12(b) of the Act:
None
Securities registered pursuant to Section 12(g) of the Act:
Common Stock, par value $.01 per share
(Title of Class)
Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes X No
--- ---
Indicate by check mark if disclosure of delinquent filers pursuant to
Item 405 of Regulation S-K is not contained herein, and will not be contained,
to the best of Registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. [X]
The aggregate market value of the voting stock of the Registrant held
by non-affiliates based on the closing sale price of the common stock on
November 23, 1998 was $540,236,616.
As of November 23, 1998, the Registrant had 68,687,259 shares of common
stock outstanding.
<PAGE>
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the Registrant's Proxy Statement for its Annual Meeting of
Shareholders to be held on February 23, 1999 are incorporated by reference into
Part III of this Report.
================================================================================
<PAGE>
This Form 10-K may contain certain "forward-looking statements" as
such term is defined in the Private Securities Litigation Reform Act of 1995 or
by the Securities and Exchange Commission in its rules, regulations and
releases, which represent the Company's expectations or beliefs, including, but
not limited to, statements concerning industry performance, the Company's
operations, economic performance, financial condition, growth and acquisition
strategies, margins and growth in sales of the Company's products. For this
purpose, any statements contained in this Report that are not statements of
historical fact may be deemed to be forward-looking statements. Without limiting
the generality of the foregoing, words such as "may," "will," "expect,"
"believe," "anticipate," "intend," "could," "estimate" or "continue" or the
negative or other variations thereof or comparable terminology are intended to
identify forward-looking statements. These statements by their nature involve
substantial risks and uncertainties, certain of which are beyond the Company's
control, and actual results may differ materially depending on a variety of
important factors, including uncertainty related to acquisitions, government
regulation, managing and maintaining growth, the effect of adverse publicity,
litigation, reliance on independent distributors of Rexall Showcase, the
centralized location of the Company's manufacturing operations, availability of
raw materials, risks associated with international operations, competition,
product liability claims, volatility of stock price and those factors described
in this and other Company filings with the Securities and Exchange Commission.
PART I
ITEM 1. BUSINESS.
General
Rexall Sundown, Inc. (the "Company") develops, manufactures, markets
and sells vitamins, herbals, nutritional supplements and consumer health
products through three channels of distribution: sales to retailers; direct
sales through independent distributors; and mail order. The Company offers a
broad product line of approximately 1,000 products consisting of approximately
1,200 stock keeping units ("SKUs"), including vitamins in both multivitamin and
single-entity formulas, minerals, herbals, homeopathic remedies, weight
management products and personal care products.
On January 29, 1998, the Company consummated a business combination
with Richardson Labs, Inc. ("Richardson") in a transaction accounted for as a
pooling of interests. Richardson is engaged in the development, marketing, sale
and distribution of a comprehensive line of diet and weight management products
under the Richardson Labs(R) brand including the number one selling natural diet
product, Ultra Chroma Slim(R), to major retailers and distributors in the food,
drug, mass, health food and television home shopping channels of trade.
The Company's principal executive offices are located at 6111 Broken
Sound Parkway, NW, Boca Raton, Florida 33487 and its telephone number is (561)
241-9400. As used herein, the "Company" means Rexall Sundown, Inc. and its
subsidiaries, except where the context indicates otherwise.
Industry Overview
As reported by industry sources, the annual domestic retail market for
vitamins, nutritional supplements and minerals was $7.8 billion in 1997,
representing a 20% increase over 1996. However, recent market data reported that
the industry growth rate was 15% for the four-week period ended October 11,
1998 compared to the prior year, down 3.7% sequentially, and no assurances can
be given as to future industry growth rates. In the last several years, public
awareness of the positive effects of vitamins and nutritional supplements on
health has been heightened by widely publicized reports of scientific findings
supporting such claims. Recent studies have indicated a correlation between the
regular consumption of selected vitamins and nutritional supplements and reduced
incidences of a wide range of conditions including cancer, heart disease,
stroke, arthritis, osteoporosis, mental fatigue and depression, declining immune
function, macular degeneration, memory loss and neural tube birth defects. The
Company believes that the rise of alternative medicine and the holistic health
movement has also contributed to increased sales of nutritional supplements.
The Company expects that the aging of the United States population,
together with a corresponding increased focus on preventative health measures,
will result in increased demand for vitamins and nutritional supplement
products. According to the United States Census Bureau, through 2010, the
35-and-older age group of consumers, which represents a substantial majority of
regular users of vitamin and nutritional supplements, is expected to grow
significantly faster than
<PAGE>
the general United States population. Based on a national survey indicating that
approximately 38% of Americans consumed vitamins and nutritional supplements on
a regular basis in 1997, the Company believes that there is a large untapped
domestic market for vitamins and nutritional supplements. Industry sources also
report that vitamin consumers are taking more vitamins and nutritional
supplements per day than in the past.
The primary channels of distribution in the vitamin and nutritional
supplement industry are: (i) mass market retailers which include drug stores,
supermarkets, mass merchandisers and discount stores; (ii) health food stores;
(iii) direct sales organizations; and (iv) mail order. Within the mass market
retailer channel, there are four primary vitamin product categories: national
brands, broadline brands, private label brands and other brands. According to
industry sources, the market for national brands, broadline brands and other
brands of vitamins in the mass market has increased from approximately 60% of
total domestic vitamin dollar sales in 1995 to approximately 65% in 1997. The
market for private label vitamins has decreased from approximately 40% in 1995
to approximately 35% in 1997 of such sales. The national brand category
primarily consists of multivitamin and mineral products marketed under
nationally advertised names such as Centrum(R), One-A-Day(R), Theragran(R) and
Osteo-Bi-Flex(TM), the Company's Sundown product which helps promote healthy,
mobile joint function. Broadline brands, such as the Company's Sundown(R)
brand, offer a complete range of products under one brand name, including
multivitamins, single-entity vitamins, minerals and nutritional supplements,
including herbal products. Private label products which are usually marketed
under the retailer's store brand name also offer a wide product assortment,
albeit somewhat narrower in scope than broadline brands, including national
brand equivalent formulas positioned as lower-priced "compare and save"
products.
While the retail channel of distribution for vitamins and nutritional
supplements has been consolidating, there has not yet been any significant
consolidation among the companies that manufacture and sell these products. The
vitamin and nutritional supplement industry remains fragmented, and the Company
believes that no company controls more than 10% of the market.
Sales by Distribution Channel
Set forth below for the periods indicated are the net sales and
percent of net sales of the Company's products through the Company's three
current distribution channels. Certain amounts have been restated to conform to
the 1998 presentation with respect to the Richardson transaction.
<TABLE>
<CAPTION>
Fiscal Year Ended August 31,
------------------------------------------------------------------------------------------------------
Distribution Channel 1998 1997 1996 1995 1994
-------------------- ------------------- ------------------ ----------------- ------------------ -------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
Sales to Retailers(1):
Sundown $ 282,909 53.3% $ 108,081 37.2% $ 71,387 33.1% $ 62,427 37.0% $ 54,216 45.7%
Other(2) 72,706 13.7% 60,648 20.9% 51,706 23.9% 37,525 22.3% 19,374 16.3%
---------- ------- --------- ------ --------- ------- --------- ------ --------- -------
Total sales to retailers 355,615 67.0% 168,729 58.1% 123,093 57.0% 99,952 59.3% 73,590 62.0%
Direct Sales:
Rexall Showcase(R) 158,910 29.9% 105,221 36.2% 76,483 35.4% 52,606 31.2% 29,510 24.9%
Mail order - SDV(R) 16,216 3.1% 16,673 5.7% 16,442 7.6% 15,979 9.5% 15,559 13.1%
---------- ------- --------- ------ --------- ------- --------- ------ --------- -------
Total net sales $ 530,741 100.0% $ 290,623 100.0% $ 216,018 100.0% $ 168,537 100.0% $ 118,659 100.0%
========== ======= ========= ====== ========= ======= ========= ====== ========= =======
</TABLE>
(1) Certain prior period amounts have been reclassified to conform to the 1998
presentation.
(2) Includes Richardson, Rexall(R), Rexall Managed Care(R), Thompson(R) and
private label.
Sales to Retailers
For its sales of vitamins and nutritional supplements to retailers,
the Company employs a marketing strategy directed at the end-user, with an
emphasis on educating these consumers. The Company provides a wide product
selection with many unique formulations, value pricing, clear and informative
labeling, timely and innovative product introductions, and specially designed
shelf organization systems called planograms. Net sales to retailers have grown
from $73.6 million in fiscal 1994 to $355.6 million in fiscal 1998.
Sundown. The Company has been selling vitamins and nutritional
supplements under the Sundown tradename since 1976. The Sundown brand offers a
broad selection of high quality products at prices lower than comparable-quality
branded vitamins, thereby creating value for consumers as well as higher rates
of shelf inventory turnover for retailers. The Company believes that its retail
customers ultimately experience increased profits per linear shelf foot due to
the high sales velocity of the Sundown brand. According to data from Information
Resources, Inc. ("IRI"), a retail information gathering service, for the 52-week
period ending September 27, 1998, Sundown was the number one brand in dollar and
unit sales in the broadline vitamin category across all food, drug and mass
merchandiser
2
<PAGE>
retail outlets in the United States. For the same period, the Sundown brand of
herbals was the number one selling herbal brand in dollar and unit sales across
all food, drug and mass merchandiser retail outlets in the United States.
Additionally, Sundown's best selling product, Osteo-Bi-Flex, which helps to
promote healthy mobile joint function is the second best selling branded
nutritional supplement in the United States and is one of ten Sundown items
among the top fifty nutritional supplement items sold nationwide.
Historically, a majority of the Sundown brand sales were to regional
deep discount retailers. Over the past several years, the success of the
Company's value pricing strategy and high sales velocity has enabled the Company
to increase its sales to retailers such as mass merchandisers, chain drug
stores, supermarkets and warehouse club chains. Sundown products are now sold by
many mass merchandisers (including chainwide distribution in all Wal*Mart,
Kmart, Target, Meijer and Shopko stores), chain drug stores (including chainwide
distribution in Rite-Aid, Walgreens, American Drug, Eckerd, Phar-Mor and Drug
Emporium stores), supermarkets (including chainwide distribution in Publix,
Kroger, Winn-Dixie, American Stores, SuperValu and Pathmark stores) and
warehouse club chains (including Sam's Club and BJ's Wholesale), as well as
through United States military commissaries and exchanges worldwide. Sundown's
net sales have increased from $54.2 million in fiscal 1994 to $282.9 million in
fiscal 1998.
The Company sells approximately 260 vitamins, herbals and nutritional
supplements under the Sundown tradename, including, among others, vitamin C,
vitamin E, multivitamins, folic acid, calcium, potassium, magnesium, iron, St.
John's Wort, ginkgo biloba, echinacea, saw palmetto and food supplements.
Vitamins and nutritional supplements are sold in varying potency levels as
single-entity supplements or multivitamin combinations, and are offered in
tablet, two-piece capsule, softgel, liquid, chewable, and powder forms to
accommodate various consumer preferences. The Company also offers national brand
comparisons under the Sundown brand which have comparable multivitamin formulas
to such products as Centrum(R), One-A-Day(R) and Theragran(R).
The Company monitors new and developing health and nutrition trends in
order to anticipate consumer demand and to introduce new products and
reformulate existing products. Examples of the Company's anticipation of and
response to consumer demand and emerging health and nutrition trends in the past
year include the introduction of (i) a maximum strength formula of its
Osteo-Bi-Flex product, a patented combination of the two dietary ingredients,
glucosamine and chondroitin, which ingredients are featured in the New York
Times bestseller, The Arthritis Cure, and reported in various clinical studies
to provide nutritional benefits which may help to promote healthy, mobile joint
function and connective tissue health; (ii) nine new standardized herbal complex
formulas under the "Xtra(TM)" trademark including St. John's Wort Xtra(TM) for
mood enhancement, Ginkgo Biloba Xtra(TM) for mental alertness, and Kava Kava
Xtra(TM) for a calming and soothing sense of well-being, which herbs have been
featured in numerous articles, including a recent cover story in Time magazine,
and on television news magazines such as ABC News' 20/20 and Primetime Live and
NBC News' Dateline; (iii) Memory Care(TM), containing the dietary ingredient,
phosphatidylserine, which promotes healthy brain function and memory; (iv)
Homocysteine Defense Formula, formulated to help maintain healthy levels of
homocysteine in the blood, the elevation of which has been identified as a
possible risk factor for cardiovascular disease as reported in the Journal of
the American Medical Association; (v) Cernitin AF(TM), containing the dietary
ingredient, Cernitin, which promotes prostate health; and (vi) Coenzyme Q-10 in
a 75mg and 150 mg dosage for helping to maintain a healthy heart, circulatory
and immune function. Historically, the Company has not incurred material
research and development expenses. During the last fiscal year, the Company
began to devote significantly greater resources to research and product
development and intends to continue this practice in the future. Product
concepts are internally developed by the Company's research and product
development team, which consists of representatives of the Company's research
and product development, sales and marketing, purchasing, quality control,
regulatory and finance departments and members of senior management. See
"--Research and Product Development."
The Company markets its Sundown vitamin and nutritional supplements
internationally through a network of distributors. The Company has exclusive and
non-exclusive distribution agreements in foreign countries throughout the world,
with the majority of international revenues presently being generated from South
America. The Company believes that certain markets in South America, the Middle
East and the Far East represent the most attractive outlets for
3
<PAGE>
its products although, currently, the Company's international sales are not
material. All international sales are settled in United States currency.
Other Sales to Retailers. In addition to Sundown products, the
Company's other sales to retailers include sales under the Rexall brand to
dollar stores and food and drug wholesalers, the Thompson brand to health food
stores, the Rexall Managed Care brand to health maintenance organizations
("HMOs"), hospitals and long-term care facilities, the Richardson Labs brand to
major retailers and distributors in the food, drug, mass and health food
channels of trade and private label products to selected mass merchandisers and
drug stores.
In 1989, the Company purchased the Rexall tradename, under which
health products have been marketed since 1903. An independent study has shown
that the Rexall tradename is widely recognized by households in the United
States. Although the Company owns the Rexall trademark, none of the operating
Rexall Drug Stores are owned by the Company or have any obligation to purchase
products from the Company. The Company's marketing strategy with respect to its
Rexall line is to emphasize a national branded product at generic prices. The
Company markets a full line of approximately 125 moderately-priced vitamins and
nutritional supplements under the Rexall tradename, primarily to dollar stores
and food and drug wholesalers. In fiscal 1998, the Company gained chainwide
distribution of Rexall products in Dollar General stores.
In 1990, the Company acquired the operating assets, including the
Thompson trademark, of Wm. T. Thompson Co., Inc. which was founded in 1935. The
"Rainbow" line of Thompson vitamins is sold through health food stores and
consists of approximately 140 products, many of which have high potencies and
are unique to Thompson. The Rainbow line represents the Company's premium line,
and is priced competitively with other similar vitamin products sold in health
food stores. Because the Company's targeted customer for Thompson products is
the sophisticated vitamin consumer, the Company's strategy includes constantly
monitoring new and developing trends in health and nutrition and adapting its
product offerings accordingly.
In 1995, the Company formed its Rexall Managed Care Division to market
vitamins and nutritional supplements to the managed care market with a focus on
HMOs, hospitals and long-term care facilities. The Rexall Managed Care line
currently consists of approximately 55 vitamin and herbal products.
In 1998, the Company acquired Richardson, which markets and sells a
comprehensive line of approximately 70 diet and weight management products under
the Richardson Labs brand to major retailers and distributors in the food,
drug, mass, health food and television home shopping channels of trade.
While the Company does not emphasize private label manufacturing, in
select instances the Company offers these products to accommodate certain
customer requests. For fiscal 1998 and 1997, approximately 3.5% and 4.3%,
respectively, of the Company's net sales were from private label products.
Direct Sales Through Independent Distributors
In 1990, the Company formed Rexall Showcase International, Inc.
("Rexall Showcase"), its network marketing subsidiary, to market and sell unique
health and wellness products under the Rexall tradename exclusively through a
sales force of independent distributors who are not employees of Rexall Showcase
or the Company. Rexall Showcase offers approximately 150 products which include
weight management products, homeopathic medicines, personal care products,
health and nutritional supplements and water filtration systems. Rexall Showcase
products are specially formulated and packaged only for the network marketing
distribution channel and are not available through retailers. New products
introduced by Rexall Showcase in fiscal 1998 include Proportion Bars(TM) in four
flavors, the Meno-Basics(TM) Companion Pack, Men's Formula Plus(TM), Women's
Formula Plus(TM), and H-Care(TM). Rexall Showcase also added two shampoos, a
hair conditioner and hand lotion to its Aestival skin care line and two new
water filtration systems to its Clear Source line. Rexall Showcase's independent
distributors are not required to make any inventory purchases and, to become a
distributor, must only purchase a distributor kit. Rexall Showcase began its
international expansion in 1996 by commencing operations in South Korea and
Mexico. In 1997, Rexall Showcase commenced operations in Hong Kong and, in
October 1998, commenced operations in Taiwan. Rexall Showcase intends to
commence operations in the largest
4
<PAGE>
market for network marketing in the world, Japan, in 1999 and selected other
countries in the future. Rexall Showcase's net sales have increased from $29.5
million in fiscal 1994 to $158.9 million in fiscal 1998.
To become a Rexall Showcase distributor, a person or entity must enter
into a standard distributor agreement with Rexall Showcase which obligates that
person to abide by Rexall Showcase's policies and procedures. Additionally,
distributors are also required to purchase a distributor kit, which includes all
of the materials necessary for a distributor to commence operating a Rexall
Showcase distributorship including information about the Company, product
information, Rexall Showcase support functions, training materials, the
ProfitPlus(TM) compensation program, policies and procedures, order forms,
application forms and sales aids, for $49.50 in the United States, which
approximates the cost of producing the distributor kit and associated costs. The
number of active Rexall Showcase distributors as of August 31, 1998 was
approximately 100,000. An "active" Rexall Showcase distributor is defined to
mean any distributor who is eligible to participate in the Rexall Showcase
business, including all new applicants whose completed distributor application
and agreement has been accepted by Rexall Showcase, as well as those existing
distributors who have renewed their distributorship during the last twelve
months. In order to renew an existing distributorship, a distributor is required
to submit to Rexall Showcase, on each anniversary date of becoming a
distributor, a renewal form with the applicable renewal fee (currently $15.00
in the United States) which approximates administrative costs and the costs of
periodic mailings.
Rexall Showcase processes, fills and ships orders from the Company's
distribution center, usually within a 24-hour period after the order is placed
by the distributor. Rexall Showcase allows its retail customers to return any
product, for any reason, to the selling distributor within 30 days from the date
of purchase for a total refund or replacement. Rexall Showcase then reimburses
the selling distributor who has issued the refund or replacement. Prior to
placing orders for additional products, distributors are required to certify
that they have sold at least 70% of their prior order. In the event of
termination of the relationship between Rexall Showcase and a distributor,
Rexall Showcase will repurchase from such distributor all resaleable inventory
purchased by such distributor within 12 months of such termination for 90% of
the original net cost to the distributor. The Company provides for a reserve for
such returns, however, to date, such returns have not been material.
Rexall Showcase's success is dependent upon continued sales of its
products to consumers by its distributors and the ongoing recruitment and
maintenance of a motivated, experienced network of distributors. To increase its
distributor's ability to succeed, Rexall Showcase sponsors and conducts national
and international conventions which are designed to educate and recruit
distributors. Distributor leaders also hold regional and local events to recruit
new distributors and train existing distributors. Rexall Showcase maintains a
dedicated distributor services department to provide information and assistance
to distributors including a national voice-mail system, a bi-monthly magazine,
national broadcast telephone calls led by top distributors and other supportive
programs. Rexall Showcase also offers participation in a stock option plan and
stock purchase plan to distributors who reach certain sales targets.
Rexall Showcase employs various technologies and innovations which
allow for fast and efficient communication and service between Rexall Showcase,
its distributors and their customers. These include such tools as (i) the
Autoship program, which allows products to be regularly shipped each month
directly from Rexall Showcase to the end-user; and (ii) voice mail, which allows
Rexall Showcase or its distributors to send phone messages to large numbers of
distributors at once or communicate to specific distributors. In fiscal 1998,
Rexall Showcase introduced REX, an automated voice response system that enables
distributors to place orders and check sales volume 24 hours a day, seven days a
week, and RSI Online, a password-protected section of its new website where
distributors may place orders, check sales volume and process new distributor
applications at any time.
Rexall Showcase is a member of the Direct Selling Association and the
World Federation of Direct Selling Associations, the national and international
trade associations, respectively, of the leading firms that manufacture and
distribute goods and services directly to consumers, whose mandate is to ensure
that the marketing by member companies of products or the direct sales
opportunity is conducted at the highest level of business ethics and service to
consumers.
5
<PAGE>
Mail Order
The Company's mail order division markets products primarily under its
SDV brand directly to consumers through catalogs and direct mailings. This
division targets approximately 350,000 of the most active customers out of an
approximate 600,000 household proprietary mailing list developed by the Company
since its inception in 1976. The Company's SDV division offers approximately 230
products including a full line of vitamins, minerals and other nutritional
supplements along with selected health-related products at prices which are
competitive with those of other mail order companies. Net sales for the
Company's SDV division have increased from $15.6 million in fiscal 1994 to $16.2
million in fiscal 1998. As the Company has focused primarily on its Sundown
brand and Rexall Showcase, the Company has not allocated significant resources
to its mail order division.
Sales Support and Customer Services for Retailers
The Company utilizes its information systems and staff of sales and
customer support professionals to provide retailers with a comprehensive array
of services. The Company seeks to assist the retailer with sales initiatives,
sales data analyses and marketing and merchandising programs, all of which are
designed to maximize in-store awareness of the Company's products and improve
results in the retailer's vitamin and nutritional supplement category. For a
number of its retail customers, the Company serves as a category manager, at no
additional cost to the retailer, actively analyzing, monitoring and advising on
product selection, profitability, sales velocity and overall performance of the
retailer's entire vitamin and nutritional supplement category. To help optimize
the performance of its retailers' departments, as well as sales of the Company's
products, the Company develops computerized planograms designed to efficiently
utilize shelf space and direct consumers' attention to the Company's products.
In addition, the Company provides marketing support for its product
lines by developing customized marketing programs. The Company's corporate
creative services department provides customer support by designing packaging
displays and point of purchase material for customers as well as informative,
easy-to-read labels and packages for the Company's products. The Company
believes that its double-sided label gives it a shelf-facing advantage
appreciated by retailers. Support for retail sales is further provided through
various in-store merchandising centers, including information pamphlets for
consumers, displays featuring key and topical products. The Company employs and
contracts with merchandisers who periodically visit certain retailers to restock
the shelves, place new orders and monitor and update the presentation of the
Company's product lines through floor displays, side wings, shelf-talkers, store
signs, promotional packs and other individualized promotions.
The Company historically expended approximately 2% of its sales on
advertising which primarily consisted of cooperative support to retailers and
brand advertising on a limited basis. During the fourth quarter of fiscal 1997,
the Company launched a major national advertising campaign to support
Osteo-Bi-Flex, the Sundown division's exclusive patented formula of glucosamine
and chondroitin. In fiscal 1998, the Company spent approximately $14 million on
television, radio and print advertisements which focused primarily on Sundown's
Osteo-Bi-Flex, St. John's Wort, Homocysteine Defense Formula and the entire line
of Sundown herbal products as well as Richardson's Chroma-Slim product. The
Company also spent approximately $8.5 million on cooperative advertising in
fiscal 1998. The Company sponsors various sports personalities and events. In
addition, Sundown is the official vitamin brand of the National Football
League's Miami Dolphins and is the preferred nutritional supplier of vitamins
and nutritional supplements for the National Hockey League's Florida Panthers.
The Company expects to continue to use various forms of mass media
advertisement, including national advertising, to primarily build the national
reputation and recognition of its Sundown brand.
At November 1, 1998, the Company had a total sales and support staff
of approximately 130 employees, of which approximately 45 are responsible for
generating sales and managing customer accounts and are paid on a salary and
incentive bonus basis. In addition, the Company utilizes a national brokerage
alliance of approximately 55 independent representative organizations in the
United States and internationally, substantially all of which sell the Company's
brands on an exclusive basis in their respective product categories.
6
<PAGE>
Research and Product Development
The Company's research and product development department consists of
an internal staff of professionals including several Ph.D.s. The staff also
includes biochemists, nutritionists, dieticians, pharmacists, food scientists
and marketing professionals. The core strategy employed by the Company's
research and product development team in developing new products is to identify
emerging markets and to develop effective, science-based formulas and
technologies for those markets. New product ideas are generated from a variety
of sources, including independent and Company-sponsored scientific and market
research, reports in scientific and medical periodicals such as the New England
Journal of Medicine and Journal of the American Medical Association and
information and suggestions received from vendors and others.
In order to determine the feasibility of developing, producing and
selling a new product, the Company's research and product development group
submits new product ideas to representatives of the Company's sales and
marketing, purchasing, manufacturing and finance departments and to members of
senior management. As part of this overall feasibility analysis, the Company's
quality control and regulatory departments also conduct a thorough investigation
of the safety and efficacy of each proposed new product as well as an analysis
of potential patent, trademark and other legal and regulatory issues. The
Company's purchasing department then obtains the raw materials necessary to
produce the new product. After quality testing, the Company begins production of
an initial pilot sample to determine various product characteristics and ensure
that this product will meet all applicable regulatory and internal quality
standards. Based on these tests, final labels and product specifications,
including any substantiated statements of nutritional support, such as structure
and function claims for the new product, are developed. The final costs of
production are reviewed by the financial and marketing teams, to determine that
adequate margins can be obtained based on the anticipated sales price. The
Company has typically been able to complete the cycle from product concept to
final production in a period ranging from several weeks to several months.
During fiscal 1998, the Company introduced 48 new products for Sundown including
the line of herbal Xtra products, soy isoflavones and alpha-lipoic acid, 11
new products for Rexall Showcase including the Meno-Basics Companion Pack,
H-Care and Proportion Bars, and 42 new products for the Company's other
divisions.
The Company is an active member and supporter of many scientific and
educational industry organizations including the Council for Responsible
Nutrition, the American Botanical Council, the American College of Nutrition,
the American Herbal Products Association, the American Herbal Pharmacopoeia, the
Herb Research Foundation, the National Nutritional Foods Association and the
National Research Council for Health ("NRCH"). The Company is also a founding
member of the Corporate Alliance for Integrative Medicine, a not-for-profit
organization created to increase knowledge and awareness of the efficacy and
safety of vitamins, herbs and other dietary supplements. The Company's research
and product development group works closely with the NRCH and its scientific
advisory board in developing continuing education programs for health
professionals. The NRCH also manages much of the Company's clinical research.
The Company, by itself and in conjunction with suppliers of raw materials,
sponsors double-blinded, placebo-controlled human investigations conducted by
leading scientific and educational institutions.
Manufacturing and Quality Control
The Company began manufacturing vitamin tablets at its 82,000 square
foot plant in Boca Raton, Florida in 1994 and expanded its manufacturing
capacity for two-piece capsules in 1997. These internal capabilities enable the
Company to better control the supply, cost and quality of goods produced.
Currently, the Company manufactures approximately 75% of its tablet and
two-piece formulations. The balance of the Company's vitamins and nutritional
supplement products are obtained from independent manufacturers in accordance
with the Company's standards and specifications. The Company intends to start
manufacturing softgels during fiscal 1999. The Company will continue to weigh
the costs and benefits of in-house manufacturing of specific products in order
to maximize cost-effectiveness and customer service. The Company's manufacturing
and distribution operations employ approximately 725 persons. The Company
enhanced its distribution capacity by opening a 65,000 square foot Western
distribution facility in Sparks, Nevada in October 1996 and by acquiring a
157,000 square foot warehousing and packaging facility in Deerfield Beach,
Florida which opened in
7
<PAGE>
December 1997. In September 1998, the Company leased an additional 50,000 square
foot warehousing and point-of-purchase display assembly facility in Deerfield
Beach, Florida.
The Company is committed to providing the highest quality products.
All of the Company's products are manufactured in accordance with the applicable
Current Good Manufacturing Practices ("CGMPs") of the United States Food and
Drug Administration ("FDA") applicable to food and other applicable regulatory
and compendial manufacturing standards, such as the United States Pharmacopoeia
("USP"). All raw materials and finished products undergo numerous quality
testing procedures, including sample, weight, purity, heavy metals and
microbiological testing. The Company follows USP monographs for microbial limit
tests, and for analytical testing methods, official, compendial or in-house
validated methods are employed. In-house validated methods developed by in-house
chemists are subject to rigorous validation prior to their adoption. In addition
to quantitative testing procedures that are used to analyze vitamins, minerals
and standardized herbal supplements, the Company utilizes state of the art
methodologies to characterize and verify whole herb raw materials. Such
methodologies include microscopy, Thin Layer Chromatography, Fourier Transform
Infrared Spectroscopy, Microscopic Image Analysis and High Performance Liquid
Chromatography. The Company also has its products tested on a periodic basis
by independent third party laboratories.
Upon receipt by the Company of a raw material or a finished product at
its manufacturing facilities, the item is placed in quarantine until tested and
passed by the Company's technical services department. When the raw materials
are released from quality control, they are ready to enter the production
process where they are blended and made into tablets or two-piece capsules. The
principal raw materials used in the manufacturing process are natural and
synthetic vitamins and other dietary ingredients, which are purchased by the
Company from domestic and international raw materials suppliers and are believed
to be readily available from numerous sources. Although the Company believes
that all of its sources of raw materials and products are reliable, the
Company's results of operations could be adversely impacted if it is forced, on
short notice, to find alternate sources of supply.
Twice a year, Shuster Laboratories, Inc. ("Shuster"), an
industry-recognized independent quality control expert, conducts extensive
audits of the Company's facilities. These inspections are conducted to assess
the level of compliance to CGMP regulations at the facilities, and also to
assess the Company's compliance with Manufacturing Practices for Nutritional
Supplements, USP 23rd Edition. Shuster is nationally recognized as a premier
quality control auditor, and performs similar quality control checks on many of
the major dietary supplement manufacturers in the United States. Each year since
the inception of the audits in November 1995, Shuster has awarded the Company
its highest rating issued to any Shuster-inspected dietary supplement firm,
based on its review of the Company's manufacturing, laboratory testing and
quality control procedures.
Government Regulation
The manufacturing, processing, formulation, packaging, labeling and
advertising of the Company's products are subject to regulation by one or more
federal agencies, including the FDA, the Federal Trade Commission ("FTC"), the
Consumer Product Safety Commission, the United States Department of Agriculture,
the United States Postal Service, the United States Environmental Protection
Agency and the Occupational Safety and Health Administration. These activities
are also regulated by various agencies of the states and localities, as well as
of foreign countries, in which the Company's products are sold. In particular,
the FDA regulates the safety, labeling and distribution of dietary supplements,
including vitamins, minerals, herbs, food, OTC and prescription drugs and
cosmetics. The regulations that are promulgated by the FDA relating to the
manufacturing process are known as CGMPs, and are different for drug and food
products. In addition, the FTC has overlapping jurisdiction with the FDA to
regulate the labeling, promotion and advertising of vitamins, OTC drugs,
cosmetics and foods.
The Dietary Supplement Health and Education Act of 1994 ("DSHEA") was
enacted on October 25, 1994. DSHEA amends the Federal Food, Drug and Cosmetic
Act by defining dietary supplements, which include vitamins, minerals,
nutritional supplements and herbs, as a new category of food separate from
conventional food. DSHEA provides a regulatory framework to ensure safe, quality
dietary supplements and the dissemination of accurate information about such
products. Under DSHEA, the FDA is generally prohibited from regulating the
active ingredients in dietary supplements as drugs unless product claims, such
as claims that a product may heal, mitigate, cure or prevent an illness, disease
or malady, trigger drug status.
8
<PAGE>
DSHEA provides for specific nutritional labeling requirements for
dietary supplements and FDA's final regulations require that all dietary
supplements must be labeled in compliance with the regulations by no later than
March 23, 1999. DSHEA permits substantiated, truthful and non-misleading
statements of nutritional support to be made in labeling, such as statements
describing general well-being resulting from consumption of a dietary ingredient
or the role of a nutrient or dietary ingredient in affecting or maintaining a
structure or function of the body. On April 29, 1998, FDA issued a Proposed
Rule, "Regulations on Statements Made For Dietary Supplements Concerning the
Effect of the Product on the Structure or Function of the Body." The Proposed
Rule, when finalized, will establish criteria for determining when a statement
is a claim to diagnose, cure, mitigate, treat or prevent disease thereby making
the product an unapproved new drug. The Company anticipates that the FDA will
finalize this Proposed Rule, as well as CGMPs which are specific to dietary
supplements.
Final labeling regulations require expanded or different labeling for
the Company's vitamin and nutritional supplement products. Final CGMPs for
dietary supplements will require at least some of the quality control provisions
contained in the CGMPs for drugs. The Company cannot determine what effect such
regulations, when fully implemented, will have on its business in the future.
Such regulations could, among other things, require the recall, reformulation or
discontinuance of certain products, additional recordkeeping, warnings,
notification procedures and expanded documentation of the properties and
manufacturing processes of certain products and scientific substantiation
regarding ingredients, product claims, safety or efficacy. Failure to comply
with applicable FDA requirements can result in sanctions being imposed on the
Company or the manufacturers of its products, including, warning letters, fines,
product recalls and seizures.
On November 18, 1998, the FTC issued its "Dietary Supplements: An
Advertising Guide for Industry." Such guide provides an application of FTC law
to dietary supplement advertising and includes examples of how principles of
advertisement interpretation and substantiation apply in the context of dietary
supplement advertising. Such Guide provides additional explanation but does not
substantively change the FTC's existing policy that all supplement marketers
have an obligation to ensure that claims are presented truthfully and to verify
the adequacy of the support behind such claims. The Company believes that its
current advertising is in substantial compliance with such Guide, although no
assurances can be given in this regard.
Governmental regulations in foreign countries where the Company plans
to commence or expand sales may prevent or delay entry into a market or prevent
or delay the introduction, or require the reformulation or relabeling, of
certain of the Company's products.
Rexall Showcase is subject to regulation under various international,
state and local laws which include provisions regulating, among other things,
the operation of direct sales programs. In addition, many countries currently
have laws that would restrict or prohibit direct sales companies, such as Rexall
Showcase, from conducting business therein.
In addition, the Company cannot predict whether new domestic or
foreign legislation regulating its activities will be enacted. Such new
legislation could have a material adverse effect on the Company.
Competition
The market for the sale of vitamins and nutritional supplements is
highly competitive. There are numerous companies in the vitamin and nutritional
supplement industry selling products to retailers, including mass merchandisers,
drug store chains, independent drug stores and health food stores. Most
companies are privately held and the Company is unable to precisely assess the
size of its competitors or where it ranks in comparison to such privately held
competitors with respect to sales to retailers. No company is believed to
control more than 10% of this market.
Although Rexall Showcase competes with other health and nutritional
food companies, the Company believes its primary competition stems from other
direct sales companies. The Company competes in the recruitment of independent
sales people with other network marketing organizations whose product lines may
or may not compete with the Company's products.
9
<PAGE>
Although certain of the Company's competitors are substantially larger
than the Company and have greater financial resources, the Company believes that
it competes favorably with other vitamin and nutritional supplement companies
because of its competitive pricing, marketing strategies, sales support and the
quality, uniqueness and breadth of its product line.
Trademarks and Patents
The Company owns trademarks including trademarks registered with the
United States Patent and Trademark Office or certain other countries for its
Sundown(R), Thompson(R), Rexall Showcase International(R), Rexall(R) and other
trademarks, and has rights to use other names material to its business. In
addition, the Company has obtained trademarks for certain of its products,
processes or slogans including Plenamins(R), Super Plenamins(R), SunVite(R),
Ultra Max(R), Perfect Iron(R), Perfect Antioxidant(R), Ginstamina(R), Circus
Chews(R), Bios(R), Bios Life 2(R), Showcase Nutritionals(R), Calmplex 2000(R),
Metaba-trol(R), Cellular Essentials(R), Cardio Basics(R), Nature Force(R), PMS
Balance(R), Human Nature(R), Mature Choices(R), Multiple Choice(R), Memory
Plus(R), In-Vigor-ol(R), Reliev-ol(R), Defend-ol(R), Intern-ol(R), Traum-ex(R),
Advanced Release Technology(R), Meta-Essent-Ol(R), Richardson Labs(R), Nutra
Kids(R) and Chroma Slim(R). The Company has trademark and service mark
applications pending for Osteo-Bi-Flex(TM), Gluco-Pro 900(TM), Vascular
CompleteTM, Smokease(TM), Tomorrow's Nutrition TodayTM, Clear ThoughtsTM,
RexwebSM, RextelSM, The Best Vitamins Under the Sun(TM), Biotrol(TM),
Proportion(TM). Federally registered trademarks have perpetual life, as long as
they are renewed on a timely basis and used properly as trademarks, subject to
the rights of third parties to seek cancellation of the marks. The Company
regards its trademarks and other proprietary rights as valuable assets and
believes they have significant value in the marketing of its products. The
Company vigorously protects its trademarks against infringement. Although the
Company owns the Rexall(R) trademark, none of the operating Rexall Drug Stores
are owned by the Company or have any obligation to purchase products from the
Company. The Company owns certain patents in the United States and Canada,
including several patents relating to Rexall Showcase's Bios Life 2 and Bios
Life 2 Natural weight management products and a patent for dual-sided labels in
the vitamin industry. The Company also has certain patent applications pending
in the United States and internationally. The Company currently markets its
Osteo-Bi-Flex, which contains glucosamine and chondroitin, as the exclusive
licensee in the United States and Canada of over-the-counter dietary supplements
manufactured under two United States Patents and one Canadian Patent
Application.
Product Liability Insurance
The Company, like other manufacturers, wholesalers, distributors and
retailers of products that are ingested, faces an inherent risk of exposure to
product liability claims if, among other things, the use of its products results
in injury. The Company currently has product liability insurance for its
operations in amounts the Company believes are adequate for its operations.
There can be no assurance, however, that such insurance will continue to be
available at a reasonable cost, or if available, will be adequate to cover
liabilities. The Company requires that each of its suppliers certify that it
carries adequate product liability insurance covering the Company.
Employees
As of November 16, 1998, the Company employed approximately 1,300
persons on a full-time basis. None of the Company's employees are represented by
a collective bargaining unit. The Company believes that its relationship with
its employees is good.
10
<PAGE>
ITEM 2. PROPERTIES.
As of November 16, 1998, the Company owned or leased the following
facilities:
<TABLE>
<CAPTION>
Approximate Leased or Expiration Date
----------- --------- ---------------
Location Type of Facility Square Feet Owned of Lease
-------- ---------------- ----------- ----- --------
<S> <C>
Domestic
- --------
Boca Raton, Florida Administrative Offices 92,000 Owned --
Boca Raton, Florida Administrative Offices 58,000 Owned --
Boca Raton, Florida Manufacturing and Production 82,000 Owned --
Deerfield Beach, Florida Warehouse and Packaging 157,000 Owned --
Boca Raton, Florida Warehouse and Distribution 100,000 Owned --
Sparks, Nevada Warehouse and Distribution 65,000 Leased September 1999
Boca Raton, Florida Warehouse and Distribution 60,000 Leased March 2001
Deerfield Beach, Florida Warehouse and Distribution 50,000 Leased July 2002
Boca Raton, Florida Warehouse and Distribution 30,000 Leased Month-to-Month
International
- -------------
Hong Kong, China Administrative Offices and 7,700 Leased July 2000
Distribution
Taipei, Taiwan Administrative Offices and 12,000 Leased August 2001
Distribution
Mexico City, Mexico (1) Administrative Offices, 5,600 Leased December 2000
Warehouse and Distribution
Seoul, South Korea Administrative Offices 4,500 Leased February 1999
Seoul, South Korea Distribution 5,000 Leased March 1999
Kiheung, South Korea Warehouse 8,000 Leased April 1999
Kwangju, Pucheon, Pusan, Taegu, Regional Offices 11,000 Leased February 1999-
Taejeon and Seoul, South Korea November 1999
</TABLE>
- --------------------------------------------------------------------------------
(1) The Company also leases two small distribution service centers in
Guadalajara and Mexico City, Mexico. The Guadalajara lease expires in
August 1999 and the Mexico City lease is on a month-to-month basis.
ITEM 3. LEGAL PROCEEDINGS.
L-Tryptophan Litigation. Numerous unrelated manufacturers,
distributors, suppliers, importers and retailers of manufactured L-tryptophan
are or were defendants in an estimated 2,000 lawsuits brought in federal and
state courts seeking compensatory and punitive damages for alleged personal
injury from ingestion of products containing manufactured L-tryptophan. The
Company has been named in 27 lawsuits, of which 25 have been settled or
discontinued through November 1998 and additional suits may be filed. Prior to a
request from the FDA in November 1989 for a national, industry-wide recall, the
Company halted sales and distribution of, and also ordered a recall of,
L-tryptophan products. Subsequently, the FDA indicated that there is a strong
epidemiological link between the ingestion of the allegedly contaminated
L-tryptophan and a blood disorder known as eosinophilia myalgia
11
<PAGE>
syndrome ("EMS"). Investigators at the United States Center for Disease Control
suspect that a contaminant was introduced during the manufacture of the product
in Japan. While intensive independent investigations are continuing, there has
been no indication that EMS was caused by any formulation or manufacturing fault
of the Company's supplier or any of the other companies that manufactured
tablets or capsules containing L-tryptophan.
The Company and certain companies in the vitamin industry, including
distributors, wholesalers and retailers, have entered into an agreement (the
"Indemnification Agreement") with Showa Denko America, Inc. ("SDA"), under which
SDA, a United States subsidiary of a Japanese corporation, Showa Denko K.K.
("SDK"), which appears to be the supplier of the apparently contaminated
product, has assumed the defense of all claims against the Company arising out
of the ingestion of L-tryptophan products and has agreed to pay the legal fees
and expenses in that defense. SDA has agreed to indemnify the Company against
any judgments and to fund settlements arising out of those actions and claims if
it is determined that a cause of the injuries sustained by the plaintiffs was a
constituent in the bulk material sold by SDA to the Company or its suppliers,
except to the extent that the Company is found to have any part of the
responsibility for those injuries and except for certain claims relating to
punitive damages. While the Indemnification Agreement remains in effect, the
Company and SDA have agreed not to institute litigation against each other
relating to claims based upon products containing L-tryptophan. In March 1993,
SDK entered into an agreement with the Company to guarantee the payment by its
subsidiary, SDA, pursuant to the Indemnification Agreement. However, it should
be noted, in attempting to prosecute claims against foreign nationals, complex
legal problems arise, such as jurisdiction, service of process, conflict of
laws, enforceability of judgments and cultural differences, among others.
It is the intention of the Company to hold SDA, and if necessary, SDK,
responsible for any liabilities and expenses incurred in connection with this
litigation, even if the Indemnification Agreement is terminated. SDA has posted
a revolving irrevocable letter of credit of $20 million to be used for the
benefit of the Company and other indemnified parties if SDA is unable or
unwilling to satisfy any claims or judgments. Although the parties have agreed
that the letter of credit will be replenished as needed, there can be no
assurance that such replenishment will occur or that there will be sufficient
funds available for the satisfaction of any and all claims or judgments. The
Company has product liability insurance, as does its supplier of L-tryptophan
products, which the Company believes provides coverage for all of its
L-tryptophan products subject to these claims, including legal defense costs.
Due to the multitude of defendants, the probability that some or all of the
total liability will be assessed against other defendants and the fact that
discovery in these actions is not complete, it is impossible to predict the
outcome of these actions or to assess the ultimate financial exposure of the
Company. The Company does not believe the outcome of these actions will have a
material adverse effect on the Company and, therefore, no provision has been
made in the Consolidated Financial Statements for any loss that may be incurred
by the Company as a result of these actions.
Hines Litigation. In April 1992, an action was commenced in the United
States District Court for the Southern District of Florida (CIV 92-6387) by
Patrick J. Hines, on behalf of himself and others similarly situated against the
Company, Rexall Showcase and certain of its officers. The complaint alleged,
among other things, violation of the United States securities laws, Racketeer
Influenced and Corrupt Organizations Act ("RICO") and unfair advertising with
respect to the operations of Rexall Showcase. Virtually identical lawsuits on
behalf of various plaintiffs were filed at approximately the same time against
various other direct sales companies by two law firms, including the law firm
representing Mr. Hines. The Company and Rexall Showcase filed a motion to
dismiss the complaint on numerous grounds, including failure to state a cause of
action and violations of the federal civil procedural rules. Such motion was
granted in June 1994 and the plaintiff filed a new complaint. The allegations in
Plaintiff's Second Amended Complaint were similar to the original complaint and
included additional claims of violations of various Florida statutes, including
those relating to deceptive advertising, business opportunities, franchises and
securities. On August 8, 1997, the court dismissed the claims for relief
alleging fraud in connection with the offer and sale of securities, federal
racketeering violations under RICO and state law racketeering claims, common law
fraud and deceit, illegal lottery and business opportunities state law
violations. In September 1997, Plaintiff filed a Third Amended Complaint in
response to such order. The Company and Rexall Showcase filed an answer and
asserted affirmative defenses to the Third Amended Complaint on August 17, 1998.
Although the Company believes that such lawsuit is without merit, no assurances
can be given in this regard. The Company will vigorously defend itself and
believes any adverse decision will not have a material adverse impact on the
Company or Rexall Showcase.
12
<PAGE>
Securities Class Action Litigation. In November 1998, several class
action complaints alleging violations of the federal securities laws were filed
against the Company and certain officers and directors of the Company. These
suits purport to be on behalf of all persons who purchased the Company's common
stock between March 19, 1998 and November 5, 1998. Following initial review of
the complaints which have been served, the Company believes that the allegations
are completely without merit, the lawsuits are groundless, and the Company will
vigorously defend against them, although no assurance can be given that the
Company will ultimately prevail in its defense.
Other Litigation. The Company is also involved in litigation relating
to claims arising out of its operations in the normal course of business, none
of which are expected, individually or in the aggregate, to have a material
adverse affect on the Company.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
No matter was submitted to the vote of security holders during the
fourth quarter of fiscal 1998.
13
<PAGE>
Executive Officers of the Registrant
- ------------------------------------
The following table sets forth certain information concerning the
executive officers of the Company:
<TABLE>
<CAPTION>
Name Age Position
- ---- --- --------
<S> <C>
Carl DeSantis.................... 59 Chairman of the Board
Christian Nast................... 67 Chief Executive Officer and Director
Damon DeSantis................... 34 President and Director; Chief Executive Officer of Rexall Showcase
Nickolas Palin................... 51 Senior Executive Vice President, President-Sundown Vitamins and Director
Ian Stuart....................... 47 Executive Vice President and Chief Operating Officer
Geary Cotton..................... 47 Vice President, Chief Financial Officer and Treasurer
Richard Werber................... 46 Vice President-Legal Affairs, General Counsel and Secretary
Gerald Holly..................... 56 Executive Vice President-Operations
</TABLE>
Carl DeSantis founded the Company in 1976 and has served as Chairman of
the Board of the Company since its inception, served as Chief Executive Officer
from the Company's inception to February 1997 and served as its President from
1976 to April 1995. Mr. DeSantis has had over 18 years of experience with retail
drug store companies, including Super-X Drug Stores and Walgreen Drug Stores. He
is the father of Damon DeSantis and Dean DeSantis, a Director of the Company.
Christian Nast has been Chief Executive Officer of the Company since
February 1997 and a Director of the Company since October 1993. Mr. Nast served
as President of the Company from April 1995 to February 1998. He served as Chief
Operating Officer of the Company from April 1995 to February 1997. From December
1989 to April 1995, Mr. Nast was employed by Colgate Palmolive Company as its
Executive Vice President--North America. Mr. Nast has over 40 years of
experience in the consumer products industry with companies such as
Bristol-Myers Squibb Company, Chesebrough-Ponds, Inc. and the Procter & Gamble
Company.
Damon DeSantis has been President of the Company and Chief Executive
Officer of Rexall Showcase, the Company's network marketing subsidiary, since
February 1998 and a Director of the Company since July 1988. He served as
President of Rexall Showcase from January 1993 to February 1998 and as Executive
Vice President of the Company from July 1988 to February 1998. He was a Vice
President of the Company from when he joined the Company in September 1983 until
July 1988. He is the son of Carl DeSantis and the brother of Dean DeSantis.
Nickolas Palin has been Senior Executive Vice President of the Company
since July 1998, President of the Company's Sundown Vitamins division since
September 1997 and a Director of the Company since December 1995. He served as
Senior Vice President-Sales and Marketing of the Company from August 1989 to
September 1997 and joined the Company in 1984.
Ian Stuart has been Executive Vice President and Chief Operating
Officer of the Company since joining the Company in September 1998. From March
1993 until joining the Company, Mr. Stuart served in various capacities for
Bristol-Myers Squibb Company, including as President of its Consumer Products
Group in Japan and, most recently, as President of its Mead Johnson Nutritionals
division. Prior thereto, Mr. Stuart has over 25 years of experience in the
consumer products industry with companies such as Unilever PLC,
Chesebrough-Ponds, Inc. and The Gillette Company.
Geary Cotton has been Chief Financial Officer of the Company since
August 1989, Vice President and Treasurer of the Company since March 1993 and
joined the Company in 1986. Mr. Cotton is a Certified Public Accountant.
14
<PAGE>
Richard Werber has been Vice President-Legal Affairs and General
Counsel of the Company since August 1991 and Secretary of the Company since
March 1993. Prior to that, Mr. Werber was a partner in the law firm of Holland &
Knight.
Gerald Holly has been Executive Vice President-Operations of the
Company since joining the Company in November 1997. For the prior twenty-five
years, Mr. Holly served in various capacities for Pharmavite Corp., a subsidiary
of Otsuka Pharmaceutical Company, Ltd. of Japan, including Executive Vice
President-Operations since 1992.
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS.
The Common Stock was first listed and began trading on the Nasdaq
National Market on June 18, 1993 under the symbol RXSD. In February 1998, the
Company's Common Stock became a component of the Nasdaq-100(R) Index, a
capitalization-weighted index comprising 100 of the largest non-financial stocks
listed on the Nasdaq National Market(R).
Set forth below are the high and low closing sales prices of the Common
Stock as reported on the Nasdaq National Market for the periods indicated.
<TABLE>
<CAPTION>
Common Stock
------------
High Low
---- ---
<S> <C> <C>
Fiscal Year Ended August 31, 1997:
First Quarter................................................. $19.62 $11.81
Second Quarter................................................ 16.56 11.88
Third Quarter................................................. 13.81 9.63
Fourth Quarter................................................ 19.50 13.56
Fiscal Year Ended August 31, 1998:
First Quarter................................................. $23.75 $17.13
Second Quarter................................................ 38.63 23.50
Third Quarter................................................. 38.69 30.03
Fourth Quarter................................................ 38.38 18.25
</TABLE>
The Company presently intends to retain all earnings for the operation
and development of its business and does not anticipate paying any cash
dividends on the Common Stock in the foreseeable future. Any future
determination as to the payment of cash dividends will depend on a number of
factors, including future earnings, capital requirements, the financial
condition and prospects of the Company and any restrictions under credit
agreements existing from time to time, as well as such other factors as the
Company's Board of Directors may deem relevant. The approximate number of
beneficial owners and record holders of the Common Stock as of November 17, 1998
was 17,350 and 1,400, respectively.
15
<PAGE>
ITEM 6. SELECTED CONSOLIDATED FINANCIAL DATA.
The selected consolidated financial data presented below is derived from the
Consolidated Financial Statements of the Company. The Consolidated Financial
Statements as of and for the years ended August 31, 1998, 1997, 1996, 1995 and
1994 have been audited by PricewaterhouseCoopers LLP, independent accountants.
The following information should be read in conjunction with Item 7 -
"Management's Discussion and Analysis of Financial Condition and Results of
Operations," the Consolidated Financial Statements and related notes and other
consolidated financial information included herein.
<TABLE>
<CAPTION>
Fiscal Year Ended August 31,
-----------------------------------------------------------------------
1998 1997 1996 1995 1994
------------- ------------ ------------ ------------ ------------
(In thousands, except per share data)
<S> <C> <C> <C> <C> <C>
Operating data:
Net sales $ 530,741 $ 290,623 $ 216,018 $ 168,537 $ 118,659
Cost of sales 223,231 113,675 85,350 79,249 58,884
------------- ------------ ------------ ------------ ------------
Gross profit 307,510 176,948 130,668 89,288 59,775
Selling, general and administrative expenses 201,655 122,941 95,072 69,556 46,426
------------- ------------ ------------ ------------ ------------
Operating income 105,855 54,007 35,596 19,732 13,349
Other income (expense), net 4,399 4,055 1,095 (511) 177
------------- ------------ ------------ ------------ ------------
Income before income tax provision 110,254 58,062 36,691 19,221 13,526
------------- ------------ ------------ ------------ ------------
Income from continuing operations (pro
forma) (1) 69,234 37,176 23,053 12,348 8,456
Loss from discontinued operations (2) - - - (7,976) (2,377)
------------- ------------ ------------ ------------ ------------
Net income (pro forma) (1) $ 69,234 $ 37,176 $ 23,053 $ 4,372 $ 6,079
============= ============ ============ ============ ============
Diluted income (loss) per common share (pro
forma) (1)
Continuing operations $ 0.94 $ 0.53 $ 0.36 $ 0.20 $ 0.14
Discontinued operations - - - (0.13) (0.04)
------------- ------------ ------------ ------------ ------------
Net income per share $ 0.94 $ 0.53 $ 0.36 $ 0.07 $ 0.10
============= ============ ============ ============ ============
Diluted weighted average shares outstanding 73,773 70,792 64,337 61,879 61,422
============= ============ ============ ============ ============
August 31,
-----------------------------------------------------------------------
1998 1997 1996 1995 1994
------------- ------------ ------------ ------------ ------------
Balance sheet data:
Working capital $ 220,643 $ 150,159 $ 56,623 $ 29,056 $ 20,769
Total assets 339,358 236,294 111,304 70,261 62,531
Long term debt - 3,476 1,962 779 1,085
Shareholders' equity 290,061 196,702 89,850 54,866 48,780
</TABLE>
- ---------------
(1) Pro forma net income from continuing operations reflects a pro forma tax
provision for Richardson Labs, Inc. for periods prior to the January 1998
acquisition of Richardson, as Richardson was an S corporation and not
subject to corporate income taxes.
(2) Net of tax benefit.
16
<PAGE>
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.
General
The following discussion and analysis should be read in conjunction
with the Consolidated Financial Statements, and the Notes thereto included
herein. Additionally, certain divisional data of the Company is set forth in
Item 1--"Business--Sales by Distribution Channel."
Revenue from the sale of the Company's products is recognized at the
time products are shipped. Net sales are net of all discounts, allowances,
returns and credits. Initial costs associated with acquiring sales agreements
with certain retail customers are amortized over the expected term of the
relevant agreement and the amortization of such costs is recorded as a reduction
in net sales. Approximately 96.5% and 95.7% of the Company's net sales in fiscal
1998 and 1997, respectively, were of products sold under one of the following
brand names: Sundown, Rexall Showcase, Richardson Labs, Rexall, Thompson, SDV
and Rexall Managed Care. Sales of private label products accounted for
approximately 3.5% and 4.3% of net sales for fiscal 1998 and 1997, respectively.
Cost of goods sold includes the cost of raw materials and all labor and
overhead associated with the manufacturing and packaging of the products. The
majority of the Company's products are in tablet, softgel or two-piece capsule
forms. In 1994, the Company initiated manufacturing, beginning with vitamins in
tablet form, which resulted in lower costs than outsourcing such manufacturing.
Presently, the Company manufactures approximately 75% of its tablet and
two-piece formulations. The Company's manufacturing operations are in one 82,000
square foot facility. In December 1997, the Company commenced operation of its
157,000 square foot packaging and warehouse facility. In addition, the Company
anticipates that it will commence manufacturing softgels during fiscal 1999 at
its current manufacturing facility.
Gross margins are impacted by changes in the relative sales mix among
the Company's channels of distribution. In particular, gross margins are
positively impacted if sales of the Company's direct sales subsidiary, Rexall
Showcase, increase as a percentage of net sales because such products command a
higher gross margin. In a related manner, selling, general and administrative
expenses as a percentage of net sales are typically higher if sales of Rexall
Showcase increase as a percentage of net sales because of the commissions paid
to Rexall Showcase's independent distributors. Conversely, if Rexall Showcase's
sales as a percentage of net sales decrease, gross margins will be negatively
impacted and selling, general and administrative expenses will decrease as a
percentage of net sales. Historically, operating margins from sales to retailers
and mail order have been higher than operating margins from the Rexall Showcase
division. For the upcoming year, the Company expects that Rexall Showcase's net
sales as a percentage of total net sales will remain relatively consistent with
the percentage achieved in fiscal 1998, although no assurances can be given in
this regard.
On September 28, 1998, the Company's Board of Directors authorized a
share repurchase program, which allows the Company to buy back up to $100
million of its Common Stock. Under the terms of the program, which has no
expiration date, the Company may buy shares from time to time in the open
market or in privately negotiated transactions, depending on market conditions
and other factors. As of November 20, 1998, the Company has repurchased
3,470,000 shares pursuant to the program.
On January 29, 1998, the Company exchanged 2,884,616 shares of the
Company's Common Stock for all of the common stock of Richardson Labs, Inc.
("Richardson"). Richardson develops, markets and sells diet and weight
management nutritional supplements. Prior to the transaction, Richardson was an
S corporation for Federal income tax purposes and, accordingly, did not pay U.S.
Federal income taxes. However, for periods prior to January 1998, pro forma net
income on the Company's Consolidated Statements of Operations reflects a pro
forma tax provision for Richardson, as if it were subject to corporate income
taxes. The transaction was accounted for as a pooling of interests, and,
accordingly, the Company's historical financial statements have been restated to
include the financial position and results of operations of
17
<PAGE>
Richardson for all prior periods presented. In connection with the transaction,
approximately $2.5 million of transaction costs and expenses were incurred
during fiscal 1998.
Results of Continuing Operations
The following table sets forth, for the periods indicated, certain
financial data as a percentage of net sales:
<TABLE>
<CAPTION>
Fiscal Year Ended August 31,
----------------------------
1998 1997 1996
---- ---- ----
<S> <C> <C> <C>
Net sales................................................... 100.0% 100.0% 100.0%
Cost of sales............................................... 42.1 39.1 39.5
------ ------ ------
Gross profit.............................................. 57.9 60.9 60.5
Selling, general and administrative expenses................ 38.0 42.3 44.0
------ ------ -----
Operating income.......................................... 19.9 18.6 16.5
Other income (expense), net................................. .8 1.4 .5
------ ------ ------
Income before income tax provision.......................... 20.7 20.0 17.0
Pro forma net income........................................ 13.0% 12.8% 10.7%
</TABLE>
Fiscal Year Ended August 31, 1998 Compared To Fiscal Year Ended August 31, 1997
For the fiscal year ended August 31, 1998, net sales were $530.7
million, an increase of $240.1 million or 82.6% over fiscal 1997. Of this
increase, net sales to retailers increased 110.8% as compared to fiscal 1997 and
accounted for $186.9 million of the overall increase. The increase in net sales
to retailers was primarily attributable to increased sales and distribution to
the Company's existing customer base, new account distribution as well as new
product introductions. Leading the sales growth in product introduction has been
the Company's Osteo Bi-Flex(TM) brand, an exclusively licensed, patented
combination of glucosamine and chondroitin, which may help to promote healthy,
mobile joint function and connective tissue health. Osteo Bi-Flex has become the
second best selling national brand supplement in the country. Net sales of the
Company's direct sales subsidiary, Rexall Showcase, increased by $53.7 million,
an increase of 51.0% over fiscal 1997. The increase in direct sales was
primarily due to the expansion of Rexall Showcase's independent distributor
base, which has increased approximately 30% since fiscal year end 1997 and the
successful introduction of new products. Also contributing to the sales increase
was the October 1997 commencement of Rexall Showcase's operations in Hong Kong.
Rexall Showcase currently has operations in Hong Kong, Taiwan and South Korea
and anticipates commencing operations in Japan in fiscal 1999. Currently, net
sales within this region of the world are not material when compared to the
Company's total net sales. The Company will continue to monitor the economic
situation within this region. The net increase in sales to retailers and for
Rexall Showcase was primarily due to an increase in unit volume, as pricing has
remained essentially flat. Net sales of the Company's mail order division, SDV,
remained relatively flat as compared to fiscal 1997.
Gross profit for fiscal 1998 was $307.5 million, an increase of $130.6
million or 73.8% over fiscal 1997. As a percentage of net sales, gross margin
decreased from 60.9% for fiscal 1997 to 57.9% for fiscal 1998. The decrease in
gross margin was due primarily to net sales to retailers constituting a higher
percentage of the Company's total net sales. As noted earlier, Rexall Showcase
products have a higher gross margin than products sold to retailers, and as
such, gross margins decline as Rexall Showcase's net sales decrease as a
percentage of total net sales. Also negatively affecting gross margin were
additional costs associated with the start-up of the Company's new packaging
facility and a change in product mix within the sales to retailers division, to
products that generate lower gross margins.
18
<PAGE>
Selling, general and administrative expenses for fiscal 1998 were
$201.7 million, an increase of $78.8 million or 64.0% over fiscal 1997. Of the
$78.8 million increase, $26.7 million related to the increase in sales
commissions paid to Rexall Showcase's independent distributors. Additionally,
expenses related to national advertising accounted for $11.1 million of the
increase. This increase in advertising expense is consistent with management
initiatives to further promote the Company's products. Also included in selling,
general and administrative expenses for fiscal 1998 are approximately $2.5
million in pooling of interest expenses related to the Richardson transaction
for which there was no corresponding expense in fiscal 1997. As a percentage of
net sales, selling, general and administrative expenses decreased from 42.3% for
fiscal 1997 to 38.0% for fiscal 1998. This percentage decrease was primarily the
result of increased net sales and the relatively fixed nature of such
administrative expenses, except for the commission expense of Rexall Showcase,
which is variable and comprises the majority of Rexall Showcase's selling,
general and administrative expenses.
Other income, net, increased from $4.1 million in fiscal 1997 to $4.4
million in fiscal 1998. Other income, net, is predominantly comprised of
interest income ($4.8 million in fiscal 1998 and $4.3 million in fiscal 1997)
which is derived from the investment of the Company's available cash balances.
Income before income tax provision was $110.3 million for fiscal 1998,
an increase of $52.2 million or 89.9% over fiscal 1997. As a percentage of net
sales, income before income tax provision increased from 20.0% for fiscal 1997
to 20.7% for fiscal 1998.
Pro forma net income (which includes a pro forma adjustment for income
taxes related to the Subchapter S status of Richardson) was $69.2 million, an
increase of $32.0 million or 86.2% over fiscal 1997. As a percentage of net
sales, pro forma net income increased from 12.8% for fiscal 1997 to 13.0% for
fiscal 1998 due to the reasons described above, partially offset by a higher
effective tax rate of 37.2% for fiscal 1998 as compared to 36.0% for fiscal
1997.
Fiscal Year Ended August 31, 1997 Compared To Fiscal Year Ended August 31, 1996
Net sales for fiscal 1997 were $290.6 million, an increase of $74.6
million or 34.5% over fiscal 1996. Of the $74.6 million increase, sales to
retailers accounted for $45.6 million, an increase of 37.1% over fiscal 1996.
Net sales to one national retailer increased by $30.2 million in fiscal 1997.
Initial distribution to this national retailer began during fiscal 1996 and
fiscal 1997 reflects the first full year of distribution of Sundown product
offerings at this national retailer. The remaining increase in sales to
retailers was primarily attributable to increased distribution as well as an
increase in the Company's existing customer base business. Net sales of the
Company's direct sales subsidiary, Rexall Showcase, increased by $28.7 million,
an increase of 37.6% over fiscal 1996. Net sales of the Company's mail order
division, SDV, increased by $231,000 or 1.4% over fiscal 1996. The increase in
net sales in each division was primarily due to increased unit sales.
Gross profit for fiscal 1997 was $176.9 million, an increase of $46.3
million or 35.4% over fiscal 1996. As a percentage of net sales, gross margin
increased from 60.5% for fiscal 1996 to 60.9% for fiscal 1997. The increase in
gross margin was due, in part, to an increase in net sales of products with
higher margins and improved margins as a result of manufacturing efficiencies
achieved from higher volume at the Company's manufacturing facility.
Additionally, net sales of Rexall Showcase, whose products have higher margins,
increased slightly as a percent of the Company's sales, representing 35.4% of
total Company net sales in fiscal 1996 compared to 36.2% in fiscal 1997.
Selling, general and administrative expenses for fiscal 1997 were
$122.9 million, an increase of $27.9 million or 29.3% over fiscal 1996. As a
percentage of net sales, such expenses decreased from 44.0% for fiscal 1996 to
42.3% for fiscal 1997, primarily as a result of increased net sales and the
relatively fixed nature of such expenses, except for the commission expense of
Rexall Showcase, which is variable and
19
<PAGE>
comprises the majority of Rexall Showcase's selling, general and administrative
expenses. Such commission expense increased by $14.3 million over fiscal 1996.
Other income, net, increased from $1.1 million in fiscal 1996 to $4.1
million in fiscal 1997 primarily as a result of increased interest income.
Interest income for fiscal 1997 was $4.3 million, as compared to $1.3 million
for fiscal 1996. Such increase was primarily a result of investment of the
Company's available cash balances, which were higher in fiscal 1997 than fiscal
1996, primarily due to the net proceeds of $62.3 million received from the
public offering of the Company's Common Stock in November 1996 (the "Offering").
Income before income tax provision was $58.1 million for fiscal 1997,
an increase of $21.4 million or 58.2% over fiscal 1996. As a percentage of net
sales, income before income tax provision increased from 17.0% for fiscal 1996
to 20.0% for fiscal 1997.
Pro forma net income (which includes a pro forma adjustment for income
taxes related to the Subchapter S status of Richardson) was $37.2 million for
fiscal 1997, an increase of $14.1 million or 61.3% over fiscal 1996. As a
percentage of net sales, pro forma net income increased from 10.7% for fiscal
1996 to 12.8% for fiscal 1997 due to the reasons described above and also as a
result of a lower effective tax rate of 36.0% in fiscal 1997 compared to 37.2%
in fiscal 1996 as a result of tax-free interest on certain of the Company's cash
equivalents and marketable securities.
Discontinued Operations
On August 31, 1995, the Company approved a plan to divest Pennex
Laboratories, Inc., now known as RSL Holdings, Inc. ("Pennex"), a manufacturer
of OTC pharmaceuticals which the Company acquired in September 1993. On November
17, 1995, Pennex ceased operations and on February 1, 1996, substantially all
the remaining assets of Pennex were sold for $6,495,000. The Company received a
$500,000 deposit and a collateralized note for the balance. The terms of such
note provided for interest at 12% per annum, payable monthly through March 1996.
The rate of interest increased to 18% per annum on April 1, 1996, although
interest is currently being paid at 12% with the balance accruing until the note
is due in full. The note was assigned from Pennex to the Company as partial
consideration for amounts owed to the Company by Pennex. The Company has been
recording interest income on the 12% interest paid to the Company. As of August
5, 1998, the Company extended the maturity of the collateralized note related to
the sale of the assets of Pennex to August 31, 1999. Interest continues to
accrue and is payable in accordance with the previous terms. As of November 20,
1998, the purchaser is in default under the terms of the most recent forbearance
agreement with respect to payments due to the Company and the Company is
reviewing all its options with respect to such forbearance agreement and
collateralized note. Furthermore, based on Company investigations, the Company
believes that the current fair market value of the underlying property, plant
and equipment securing the note exceeds the net book value of such property,
plant and equipment at August 31, 1998.
As of August 31, 1998, the Company had recorded net assets of
discontinued operations of $4.1 million. Assuming full collection of the balance
of the collateralized note, as to which no assurances can be given, the Company
expects to record a reduction to the estimated loss on disposition of
approximately $1.4 million (net of tax) or approximately $.02 per share, which
would be reflected as an adjustment to discontinued operations.
Quarterly Results of Operations; Seasonality
The following table sets forth certain quarterly financial data for
fiscal 1998 and 1997. This quarterly information is unaudited, has been prepared
on the same basis as the annual financial statements and, in the opinion of the
Company's management, reflects all normally recurring adjustments necessary for
fair presentation of the information for the periods presented. Operating
results for any quarter are not necessarily indicative of results of any future
period.
20
<PAGE>
<TABLE>
<CAPTION>
Fiscal 1998 Fiscal 1997
------------------------------------- --------------------------------------
First Second Third Fourth First Second Third Fourth
Quarter Quarter Quarter Quarter Quarter Quarter Quarter Quarter
------- ------- ------- ------- ------- ------- ------- -------
(Dollars in thousands, except per share amounts)
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Net sales..................... $110,720 $115,489 $150,979 $153,553 $62,078 $64,948 $75,018 $88,579
Operating income.............. 21,896 22,391 29,862 31,706 11,350 12,522 13,598 16,537
Pro forma net income(1)....... 14,543 14,688 19,380 20,623 7,475 8,780 9,539 11,382
Pro forma diluted earnings per
share (1).................. $.20 $.20 $.26 $.28 $.11 $.12 $.13 $.16
</TABLE>
- --------------------------------------
(1) Pro forma net income reflects a pro forma tax provision for Richardson
for periods prior to the January 1998 acquisition of Richardson, as
Richardson was an S corporation and not subject to corporate income
taxes.
(2) 1997 per share results for the total of the four quarters differ from
full-year per share results, as a separate computation of earnings per
share is made for each quarter presented.
The Company believes that its business is not subject to significant
seasonality based on historical trends, with the exception of Rexall Showcase
which typically experiences lower revenues in the second and fourth fiscal
quarters due to winter and summer holiday seasons, respectively.
Liquidity And Capital Resources
The Company had working capital of $220.6 million as of August 31,
1998, compared to $150.2 million as of August 31, 1997. This increase was
principally the result of increased trade accounts receivable and inventory.
Trade accounts receivable increased due to higher sales in fiscal 1998. Although
trade accounts receivable increased 113.4% over fiscal 1997 (primarily the
result of the 110.8% increase in net sales to retailers), the Company's
receivable turnover has remained consistent at approximately 47 days. The
increase in inventory is the result of higher inventory levels necessary to
support the Company's growth and anticipated future sales growth, including the
introduction of new products. Furthermore, the Company's inventory turnover has
improved to approximately 3.5 turns for fiscal 1998 as compared to approximately
3.3 turns for fiscal 1997.
Net cash provided by operating activities for fiscal 1998 was $36.9
million compared to $38.7 million for fiscal 1997. Fiscal 1998 net cash provided
by operating activities remained relatively consistent with net cash provided by
operating activities for fiscal 1997 as the increase in net income was offset by
increases in trade accounts receivable and inventory. Net cash used in investing
activities was $38.4 million for fiscal 1998 compared to $34.2 million for
fiscal 1997. The Company made capital expenditures for property, plant and
equipment of $29.1 million in fiscal 1998 and $13.5 million in fiscal 1997. The
fiscal 1998 capital expenditures primarily related to investments in the
Company's new administrative facility, facility enhancements and equipment. Net
cash provided by financing activities was $6.9 million for fiscal 1998 compared
to $64.0 million for fiscal 1997, with fiscal 1997 including $62.3 million of
net proceeds received from the Offering.
The Company believes that its existing cash balances, internally
generated funds from operations and its available bank line of credit will
provide the liquidity necessary to satisfy the Company's working capital needs,
including the purchase and maintenance of inventory and the financing of the
Company's accounts receivable, and anticipated capital expenditures for the next
fiscal year, as well as any future repurchase of shares under the Company's
share repurchase program.
21
<PAGE>
Inflation
Inflation has not had a significant impact on the Company in the past
three years nor is it expected to have a significant impact in the foreseeable
future.
Potential Year 2000 Issues
The Year 2000 issue generally refers to the inability of computer
hardware and software to properly recognize a year that begins with "20" instead
of "19." This issue arose as a result of computer systems and programs being
designed to accept a calendar year reference as two-digits as opposed to
four-digits. If the Year 2000 issue is not corrected, computer applications may
stop processing date-related computations or process them incorrectly. The
Company has recognized the severity of the Year 2000 issue and has designated it
as a priority, allocating appropriate resources in order to minimize the impact
of Year 2000 date-related problems on its business. The Company has assembled an
internal task force which is headed by its information technology vice president
to review and evaluate the Year 2000 issue as it relates to its internal
computer based and non-computer based systems as well as third party computer
systems including those of its vendors and customers. The scope of the Company's
Year 2000 analysis encompasses the Company's traditional enterprise-wide
software, its mid-range and personal computing systems, and its embedded
microprocessor systems.
For the Company's internal computer and non-computer-based systems, the
task force will identify the scope of any Year 2000 problems, prepare test
scripts in order to determine whether these systems will be Year 2000 compliant
and implement the test scripts by conducting appropriate testing in order to
confirm actual compliance. The Company expects to complete test scripts for all
of its internal computer-based systems by the end of calendar 1998. The task
force is currently in the process of identifying the applicable internal
non-computer systems which potentially may be affected by Year 2000.
In order to determine the state of readiness of third parties,
including the Company's significant vendors and customers, to handle Year 2000
issues and whether it will impact the Company's business, the Company has sent
letters of inquiry to substantially all of the third parties with whom it does
business. The Company's vendors and customers are at various stages in analyzing
this issue and the Company is in the process of receiving and analyzing their
responses to the Company's letter. The Company expects to have identified any
potential Year 2000 problems with its key vendors and customers by the end of
January 1999. The Company has not yet established any contingency plans but will
develop such plans as needed once it identifies the scope and magnitude of any
compliance issues with third parties. There can be no assurance that the systems
of other companies on which the Company's systems rely or interface will be
timely converted, which failure by a key vendor or customer could prevent the
Company's products from being distributed in a timely manner.
The Company has incurred and will continue to incur internal staff
costs as well as consulting and other expenses related to Year 2000 issues. If
any of the Company's internal systems or equipment are found to be non-compliant
with Year 2000, they will need to be upgraded or replaced. To date, none of
these costs have been material. The recent growth of the Company which prompted
it, in October 1997, to install a new enterprise-wide computer system which is
utilized for the Company's manufacturing, distribution, finance and sales
functions, substantially reduces the likelihood that the costs incurred by the
Company in becoming Year 2000 compliant will be material. This enterprise-wide
system is warranted to be Year 2000 compliant by the manufacturer and the
Company will confirm its compliance by subjecting this system to the same tests
as the Company's other internal computer-based systems. The Company does not
expect that the total costs involved in becoming Year 2000 compliant will be
material to the Company's financial position, results of operations or cash
flows.
22
<PAGE>
Recent Financial Accounting Standards Board Statements
SFAS No. 130, "Reporting Comprehensive Income," establishes standards
for reporting and display of comprehensive income and its components (revenues,
expenses, gains, and losses and changes in equity resulting from certain
transactions and economic events, other than changes reflected in the
Consolidated Statements of Operations). SFAS No. 130 is effective for fiscal
years beginning after December 15, 1997 and requires reclassification of
financial statements for earlier periods provided for comparative purposes. The
adoption of SFAS No. 130 will not affect the Company's results of operations and
financial position, but will have an impact on financial statement disclosures.
SFAS No. 131, "Disclosures about Segments of an Enterprise and Related
Information," establishes standards for the way that public companies report
selected information about operating segments in annual financial statements and
requires that those companies report selected information about segments in
interim financial reports issued to shareholders. It also establishes standards
for related disclosures about products and services, geographic areas and major
customers. SFAS No. 131 is effective for the Company's financial statements for
the fiscal year ending August 31, 1999. Although management has not completed
its assessment of SFAS No. 131, it is contemplated that the pronouncement will
require certain segregated financial disclosures related to the Company's
channels of distribution.
In April 1998, the American Institute of Certified Public Accountants'
Accounting Standards Executive Committee issued Statement of Position No. 98-5,
"Reporting on the Costs of Start-Up Activities" (SOP No. 98-5). SOP No. 98-5
requires the cost of start-up activities and organization costs to be expensed
as incurred. SOP No. 98-5 is effective for financial statements for fiscal years
beginning after December 15, 1998. The Company anticipates that the adoption of
this statement will not have a material affect on the Company's results of
operations or financial position.
23
<PAGE>
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.
Financial statements and supplementary data for the Company are on the
following pages F-1 through F-18.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE.
None.
24
<PAGE>
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
<TABLE>
<CAPTION>
Page
----
<S> <C>
Report of Independent Accountants....................................................... F-2
Consolidated Balance Sheets........................................................... F-3
Consolidated Statements of Operations................................................. F-4
Consolidated Statements of Shareholders' Equity....................................... F-5
Consolidated Statements of Cash Flows................................................. F-6
Notes to Consolidated Financial Statements............................................ F-7
</TABLE>
F-1
<PAGE>
Report of Independent Accountants
To the Board of Directors and
Shareholders of Rexall Sundown, Inc.
In our opinion, the accompanying consolidated balance sheets and the related
consolidated statements of operations, shareholders' equity and cash flows
present fairly, in all material respects, the financial position of Rexall
Sundown, Inc. and its subsidiaries at August 31, 1998 and 1997, and the results
of their operations and their cash flows for each of the three years in the
period ended August 31, 1998 in conformity with generally accepted accounting
principles. These financial statements are the responsibility of the Company's
management; our responsibility is to express an opinion on these financial
statements based on our audits. We conducted our audits of these statements in
accordance with generally accepted auditing standards which require that we plan
and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements, assessing the accounting principles used and significant estimates
made by management, and evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for the opinion expressed
above.
Our audits of the consolidated financial statements of Rexall Sundown, Inc. also
included an audit of the Financial Statement Schedule listed in Item 14(a) of
this Form 10-K. In our opinion, the Financial Statement Schedule presents
fairly, in all material respects, the information set forth therein when read in
conjunction with the related consolidated financial statements.
PricewaterhouseCoopers LLP
Fort Lauderdale, Florida
October 7, 1998, except for the fourth paragraph of Note 15 as to which date is
November 24, 1998
F-2
<PAGE>
REXALL SUNDOWN, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(Amounts in thousands, except share and per share data)
<TABLE>
<CAPTION>
August 31,
----------------------------------
1998 1997
------------ ------------
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents......................................................... $ 87,349 $ 81,943
Marketable securities ............................................................ 32,045 24,829
Trade accounts receivable, net of allowance for doubtful accounts
of $535 and $185, respectively............................................... 60,805 28,494
Inventory......................................................................... 77,727 42,739
Prepaid expenses and other current assets......................................... 7,554 7,221
Net current assets of discontinued operations..................................... 4,076 4,076
----------- -----------
Total current assets.............................................. 269,556 189,302
Property, plant and equipment, net.................................................. 56,697 34,372
Other assets........................................................................ 13,105 12,620
----------- -----------
Total assets...................................................... $339,358 $236,294
=========== ===========
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable.................................................................. $ 21,653 $ 14,509
Accrued expenses and other current liabilities.................................... 27,260 21,158
Current portion of long-term debt ................................................ - 3,476
----------- -----------
Total current liabilities......................................... 48,913 39,143
Other liabilities................................................................... 384 449
----------- -----------
Total liabilities................................................. 49,297 39,592
----------- -----------
Commitments and contingencies
Shareholders' equity:
Preferred stock, $.01 par value; authorized 5,000,000
shares, no shares outstanding................................................... - -
Common stock, $.01 par value; authorized 200,000,000 shares,
shares issued and outstanding: 72,139,459 and 70,144,634, respectively......... 721 702
Capital in excess of par value.................................................... 149,405 124,002
Retained earnings................................................................. 140,185 72,488
Cumulative translation adjustment................................................. (250) (490)
----------- -----------
Total shareholders' equity ....................................... 290,061 196,702
----------- -----------
Total liabilities and shareholders' equity........................ $339,358 $236,294
=========== ===========
</TABLE>
See accompanying notes
F-3
<PAGE>
REXALL SUNDOWN, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands, except share and per share data)
<TABLE>
<CAPTION>
Years Ended August 31,
------------------------------------------------
1998 1997 1996
------------- ------------ ------------
<S> <C> <C> <C>
Net sales.............................................................. $ 530,741 $ 290,623 $ 216,018
Cost of sales.......................................................... 223,231 113,675 85,350
------------- ------------ ------------
Gross profit.................................................. 307,510 176,948 130,668
Selling, general and administrative expenses........................... 201,655 122,941 95,072
------------- ------------ ------------
Operating income.............................................. 105,855 54,007 35,596
Other income (expense):
Interest income...................................................... 4,763 4,337 1,264
Interest expense..................................................... (218) (322) (162)
Other income (expense)............................................... (146) 40 (7)
------------- ------------ ------------
Income before income tax provision..................................... 110,254 58,062 36,691
Income tax provision................................................... 40,078 19,592 11,798
------------- ------------ ------------
Net income............................................................. $ 70,176 $ 38,470 $ 24,893
============= ============ ============
Pro forma net income .................................................. $ 69,234 $ 37,176 $ 23,053
============= ============ ============
Net income per common share:
Basic.............................................................. $ .99 $ .56 $ .39
============= ============ ============
Diluted............................................................ $ .95 $ .54 $ .39
============= ============ ============
Pro forma net income per common share:
Basic.............................................................. $ .97 $ .54 $ .37
============= ============ ============
Diluted............................................................ $ .94 $ .53 $ .36
============= ============ ============
Weighted average common shares outstanding
Basic.............................................................. 71,195,723 68,571,526 63,107,735
============= ============ ============
Diluted............................................................ 73,773,303 70,792,330 64,337,080
============= ============ ============
</TABLE>
See accompanying notes
F-4
<PAGE>
REXALL SUNDOWN, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
(Amounts in thousands, except share data)
<TABLE>
<CAPTION>
Capital in Cumulative
Number of Common Excess of Retained Translation
Shares Stock Par Value Earnings Adjustment
------ ----- --------- -------- ----------
<S> <C> <C> <C> <C> <C>
Balance at August 31, 1995......................... 22,495,316 $ 225 $ 42,174 $ 12,467 $ -
Net income...................................... - - - 24,893 -
Exercise of stock options....................... 1,244,078 13 6,469 - -
Tax benefit from exercise of options............ - - 5,000 - -
Three-for-two common stock split................ 9,805,350 98 (98) - -
S Corporation contribution by members of
Richardson Labs, Inc......................... - - 628 183 -
S Corporation distribution to members of
Richardson Labs, Inc......................... - - (10) (2,070) -
Cumulative translation adjustment............... - - - - (121)
--------------- ------------- -------------- ------------- ----------
Balance at August 31, 1996......................... 33,544,744 336 54,163 35,473 (121)
Net income...................................... - - - 38,470 -
Common stock offering........................... 2,400,000 24 62,263 - -
Exercise of stock options....................... 569,881 6 3,210 - -
Tax benefit from exercise of options............ - - 4,188 - -
Stock options issued to Rexall Showcase
distributors................................. - - 514 - -
Two-for-one common stock split.................. 33,630,009 336 (336) - -
S Corporation distribution to members of
Richardson Labs, Inc......................... - - - (1,455) -
Cumulative translation adjustment............... - - - - (369)
--------------- ------------- -------------- ------------- ----------
Balance at August 31, 1997......................... 70,144,634 702 124,002 72,488 (490)
Net income...................................... - - - 70,176 -
Exercise of stock options....................... 1,994,825 19 10,341 - -
Tax benefit from exercise of options............ - - 13,587 - -
Stock options issued to Rexall Showcase
distributors................................. - - 1,475 - -
Adjustment to conform fiscal year of
pooled entity................................. - - - (2,479) -
Cumulative translation adjustment............... - - - - 240
--------------- ------------- -------------- ------------- ----------
Balance at August 31, 1998......................... 72,139,459 $ 721 $149,405 $140,185 $ (250)
=============== ============= ============== ============= ==========
</TABLE>
See accompanying notes
F-5
<PAGE>
REXALL SUNDOWN, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands)
<TABLE>
<CAPTION>
Years Ended August 31,
----------------------------------------------
1998 1997 1996
--------- --------- --------
<S> <C> <C> <C>
Cash flows provided by (used in) operating activities:
Net income.................................................... $70,176 $38,470 $24,893
Adjustments to reconcile net income to net cash
provided by operating activities:
Depreciation............................................... 6,269 3,803 2,916
Amortization............................................... 2,098 1,523 1,202
Loss (gain) on sale of property and equipment.............. 133 6 (18)
Deferred income taxes...................................... (80) (429) 2,076
Foreign exchange translation adjustment.................... 240 (369) (121)
Stock options issued to Rexall Showcase distributors....... 1,475 514 -
Adjustment to conform fiscal year of pooled entity......... (2,479) - -
Changes in assets and liabilities:
Trade accounts receivable................................ (32,311) (12,623) (8,913)
Inventory................................................ (34,988) (10,678) (10,306)
Prepaid expenses and other current assets................ (333) (3,005) (1,745)
Other assets............................................. 183 (472) (5,501)
Accounts payable......................................... 7,144 7,367 1,550
Accrued expenses and other current liabilities........... 19,481 14,659 9,547
Other liabilities........................................ (65) 196 253
Discontinued operations - non cash charges
and changes in assets and liabilities.................. - (221) 4,153
---------- ---------- ---------
Net cash provided by operating activities ............. 36,943 38,741 19,986
---------- ---------- ---------
Cash flows provided by (used in) investing activities:
Purchase of marketable securities........................... (59,532) (37,828) (5,988)
Proceeds from sale of marketable securities................. 52,316 20,988 -
Acquisition of property, plant and equipment................ (29,078) (13,454) (5,550)
Acquisition of computer software............................ (2,478) (4,227) (1,835)
Proceeds from sale of property and equipment................ 351 18 23
Restricted cash............................................. - 278 (278)
---------- ---------- ---------
Net cash used in investing activities.................. (38,421) (34,225) (13,628)
---------- ---------- ---------
Cash flows provided by (used in) financing activities:
Borrowings under long-term facility......................... - 1,860 1,512
Net proceeds from offering.................................. - 62,287 -
Principal payments on long-term debt........................ (3,476) (346) ( 329)
Distributions to members.................................... - (3,040) (1,727)
Exercise of options to purchase common stock................ 10,360 3,216 6,482
---------- ---------- ---------
Net cash provided by financing activities.............. 6,884 63,977 5,938
---------- ---------- ---------
Net increase in cash and cash equivalents .................. 5,406 68,493 12,296
Cash and cash equivalents at beginning of period............ 81,943 13,450 1,154
---------- ---------- ---------
Cash and cash equivalents at end of period.................. $87,349 $81,943 $13,450
========== ========== =========
Supplemental disclosures of cash flow information:
Cash paid during the year for:
Interest.................................................. $ 102 $ 331 $ 164
========== ========== =========
Income taxes.............................................. $26,362 $ 13,857 $ 3,725
========== ========== =========
</TABLE>
See accompanying notes
F-6
<PAGE>
REXALL SUNDOWN, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in thousands, except share and per share data)
1. Description of Business
Business
Rexall Sundown, Inc. (the "Company") develops, manufactures, markets and
sells vitamins, herbals, nutritional supplements and consumer health products.
The Company distributes its products using three channels of distribution: sales
to retailers; direct sales through independent distributors; and mail order. The
Company offers a broad product line including vitamins in both multivitamin and
single-entity formulas, minerals, herbals, homeopathic remedies, weight
management products and personal care products.
The Company's wholly-owned operating subsidiary, Rexall Showcase
International, Inc. ("Rexall Showcase"), markets and distributes health and
wellness products under the Rexall Showcase tradename through a sales force of
independent distributors.
On January 29, 1998, the Company consummated a business combination
with Richardson Labs, Inc. ("Richardson"). Richardson develops, markets and
sells diet and weight management nutritional supplements. The transaction was
accounted for as a pooling of interests, and, accordingly, the Company's
historical financial statements have been restated to include the financial
position and results of operations of Richardson for all prior periods
presented. For further information regarding the Richardson transaction, see
Note 3.
2. Summary of Significant Accounting Policies
Principles of Consolidation
The consolidated financial statements include the accounts of the Company
and its wholly-owned subsidiaries. All significant intercompany balances and
transactions have been eliminated. Certain prior period amounts have been
reclassified to conform to the 1998 presentation.
Marketable Securities
Marketable securities consist primarily of government debt instruments
and are classified as available-for-sale securities under Statement of Financial
Accounting Standards ("SFAS") No. 115, "Accounting for Certain Investments in
Debt and Equity Securities." At August 31, 1998 and 1997 the fair value of the
securities approximated cost.
Inventory
Inventories are stated at the lower of cost (first-in, first-out basis)
or market.
Property, Plant and Equipment
Property, plant and equipment is stated at cost less accumulated
depreciation. Depreciation is charged to expense over the estimated useful lives
of the assets and is computed principally using accelerated methods. Estimated
useful lives range from 31.5 years for buildings and improvements, 5 to 7 years
for machinery and equipment and 7 years for furniture and fixtures. Leasehold
improvements are depreciated over the life of the respective lease. Maintenance
and repairs are charged to expense when incurred and betterments are
capitalized. Upon retirement or sale, the cost and accumulated depreciation are
eliminated from the accounts and the gain or loss, if any, is included in the
determination of net income as a component of other income (expense). The
Company reviews long-lived assets for impairment whenever events or changes in
circumstances indicate that the carrying amount of an asset may not be fully
recoverable.
F-7
<PAGE>
REXALL SUNDOWN, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Dollars in thousands, except share and per share data)
2. Summary of Significant Accounting Policies, continued
Intangible Assets
Intangible assets, which are included in other assets (non-current), are
stated at cost less accumulated amortization. Intangible assets are amortized on
a straight-line basis over their estimated useful lives which range from three
to fourteen years. The Company reviews its intangible assets for impairment
whenever events or changes in circumstances indicate that the carrying amount of
an asset may not be fully recoverable.
Cash Equivalents
The Company considers all highly liquid investments purchased with a
maturity of three months or less at the date of purchase to be cash equivalents.
Income Taxes
The Company utilizes the liability method of accounting for deferred
income taxes. This method requires recognition of deferred tax assets and
liabilities for the expected future tax consequences of events that have been
included in the financial statements or tax returns. Under this method, deferred
tax assets and liabilities are determined based on the difference between the
financial and tax bases of assets and liabilities using enacted tax rates in
effect for the year in which the differences are expected to reverse. Deferred
tax assets are also established for the future tax benefits of loss and credit
carryovers. The liability method of accounting for deferred income taxes
requires a valuation allowance against deferred tax assets if, based on the
weight of available evidence, it is more likely than not that some or all of the
deferred tax assets will not be realized.
Revenue Recognition
The Company recognizes revenue upon shipment, and such revenue is
recorded net of estimated sales returns, discounts and allowances.
Prepaid Customer Allowances
Costs associated with acquiring sales agreements with certain customers
are amortized over the expected terms of the agreements. These costs consist of
the cost of inventory provided at no charge and other allowances and are
included in other assets (both current and non-current). The amortization of
these costs is recorded as a reduction of net sales.
Advertising and Catalog Costs
Mail order catalog costs are expensed as incurred. Advertising production
costs are expensed when the advertising first takes place and media costs are
expensed as incurred. The Company incurred consumer advertising expenses of
$14,100 for the year ended August 31, 1998, $3,000 for the year ended August 31,
1997 and $3,300 for the year ended August 31, 1996.
F-8
<PAGE>
REXALL SUNDOWN, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Dollars in thousands, except share and per share data)
2. Summary of Significant Accounting Policies, continued
Foreign Currency Translation
The financial statements and transactions of the Company's foreign
operations, except those located in highly inflationary economies, are
maintained in their functional currency and translated into U.S. dollars in
accordance with SFAS No. 52, "Foreign Currency Translation." Assets and
liabilities are translated at current exchange rates in effect at the balance
sheet date. Translation adjustments, which result from the process of
translating financial statements into United States dollars, are accumulated in
a separate component of shareholders' equity. Revenues and expenses are
translated at the average exchange rate for each period. Gains and losses from
foreign currency transactions are included in net income. For foreign operations
in highly inflationary economies, gains and losses from balance sheet
translation adjustments are included in net income.
Use of Estimates
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates.
Net Income Per Share
During the second quarter of 1998, the Company adopted SFAS No. 128,
"Earnings per Share." SFAS No. 128 established new standards for computing and
presenting earnings per share ("EPS"). This statement replaced the presentation
of primary and fully diluted EPS and requires a dual presentation of basic and
diluted EPS. Basic EPS is computed using the weighted average number of common
shares, whereas diluted EPS is computed using the weighted average number of
common shares and potentially dilutive common shares outstanding during the
period. The Company's potentially dilutive common shares consist of common stock
options. EPS amounts for all periods have been restated to conform to the
requirements of SFAS No. 128. For the fiscal year ended August 31, 1998, options
to purchase approximately 149,000 shares of common stock (the "Common Stock"),
$.01 par value, of the Company were excluded from the diluted EPS calculation as
the options' exercise prices were greater than the average market price of the
Common Stock.
Recent Accounting Standards
SFAS No. 130, "Reporting Comprehensive Income," establishes standards
for reporting and display of comprehensive income and its components (revenues,
expenses, gains, and losses and changes in equity resulting from certain
transactions and economic events, other than changes reflected in the
Consolidated Statements of Operations). SFAS No. 130 is effective for fiscal
years beginning after December 15, 1997 and requires reclassification of
financial statements for earlier periods provided for comparative purposes. The
adoption of SFAS No. 130 will not affect the Company's results of operations and
financial position, but will have an impact on financial statement disclosures.
SFAS No. 131, "Disclosures about Segments of an Enterprise and Related
Information," establishes standards for the way that public companies report
selected information about operating segments in annual financial statements and
requires that those companies report selected information about segments in
interim financial reports issued to shareholders. It also establishes standards
for related disclosures about products and services, geographic areas and major
customers. SFAS No. 131 is effective for the Company's financial statements for
the fiscal year ending August 31, 1999. Although management has not completed
its assessment of SFAS No. 131, it is contemplated that the pronouncement will
require certain segregated financial disclosures related to the Company's
channels of distribution.
F-9
<PAGE>
REXALL SUNDOWN, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Dollars in thousands, except share and per share data)
2. Summary of Significant Accounting Policies, continued
In April 1998, the American Institute of Certified Public Accountants'
Accounting Standards Executive Committee issued Statement of Position No. 98-5,
"Reporting on the Costs of Start-Up Activities" (SOP No. 98-5). SOP No. 98-5
requires the cost of start-up activities and organization costs to be expensed
as incurred. SOP No. 98-5 is effective for financial statements for fiscal years
beginning after December 15, 1998. The Company anticipates that the adoption of
this statement will not have a material affect on the Company's results of
operations or its financial position.
3. Richardson Transaction
On January 29, 1998, the Company exchanged 2,884,616 shares of the
Company's Common Stock for all of the common stock of Richardson. Prior to this
transaction, Richardson was an S corporation for Federal income tax purposes
and, accordingly, did not pay U.S. Federal income taxes. For periods prior to
the transaction with Richardson, pro forma net income on the Consolidated
Statements of Operations reflects a pro forma tax provision for Richardson, as
if it were subject to corporate income taxes.
As a result of the transaction, Richardson's December fiscal year end
was adjusted to conform to the Company's August fiscal year end. Therefore, in
preparing the consolidated financial statements, Richardson's financial
statements for the fiscal year ended August 31, 1998 were combined with the
Company's financial statements for the same period and Richardson's financial
statements for the fiscal years ended December 31, 1997 and 1996 were combined
with the Company's financial statements for the fiscal years ended August 31,
1997 and 1996, respectively. In order to change Richardson's fiscal year end, an
adjustment of $2,479 was made to shareholders' equity to eliminate the effect of
including Richardson's results of operations for the four months ended December
31, 1997 in both fiscal 1998 and fiscal 1997.
Net sales and pro forma net income of the separate companies for the
interim period nearest the date of the combination are as follows:
<TABLE>
<CAPTION>
Rexall
Sundown Richardson Combined
------- ---------- --------
<S> <C> <C> <C>
Six months ended February 28, 1998
Net sales............................ $209,122 $17,087 $226,209
Pro forma net income................. 28,318 913 29,231
</TABLE>
In connection with the transaction, approximately $2,500 of transaction
costs and expenses were incurred during fiscal 1998.
4. Inventory
The components of inventory are as follows:
<TABLE>
<CAPTION>
August 31,
----------------------------
1998 1997
--------- ---------
<S> <C> <C>
Raw materials, bulk tablets and capsules............ $ 36,011 $ 22,275
Work in process..................................... 4,436 2,807
Finished products................................... 37,280 17,657
--------- ---------
Total inventory.................................. $ 77,727 $ 42,739
========= =========
</TABLE>
F-10
<PAGE>
REXALL SUNDOWN, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Dollars in thousands, except share and per share data)
5. Property, Plant and Equipment
Property, plant and equipment is comprised of:
<TABLE>
<CAPTION>
August 31,
----------------------------
1998 1997
--------- ---------
<S> <C> <C>
Land................................................$ 4,736 $ 2,972
Building and improvements........................... 32,125 19,987
Machinery and equipment............................. 34,827 21,468
Leasehold improvements.............................. 1,367 750
Furniture and fixtures.............................. 2,297 1,795
--------- ----------
75,352 46,972
Less accumulated depreciation and
amortization....................................... (18,655) (12,600)
--------- ----------
Property, plant and equipment, net...............$ 56,697 $ 34,372
========= ==========
</TABLE>
6. Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities are comprised of the
following:
<TABLE>
<CAPTION>
August 31,
-----------------------------
1998 1997
--------- ----------
<S> <C> <C>
Accrued commissions................................. $ 8,387 $ 5,093
Accrued salaries and bonuses........................ 5,105 2,639
Accrued customer rebates............................ 3,952 1,642
Loans payable....................................... - 2,444
Other............................................... 9,816 9,340
--------- ---------
Total accrued expenses and other
current liabilities............................ $27,260 $ 21,158
========= =========
</TABLE>
Loans payable at August 31, 1997 consisted of two short-term lines of
credit with South Korean banks, which had combined available borrowing amounts
of $3,333, for the Company's foreign subsidiary in South Korea. Such lines were
repaid in March 1998.
7. Long-Term Debt and Borrowing Arrangements
Long-term debt consisted of the following:
<TABLE>
<CAPTION>
August 31,
-----------
1997
-----------
<S> <C>
Non-compete agreement, non-interest bearing, net of discount
imputed at 8%, of $2 at August 31, 1997, maturing
in January 1998.................................. $ 105
Richardson line of credit........................... 3,371
Less current portion........................ (3,476)
----------
Total long-term debt........................ $ -
==========
</TABLE>
F-11
<PAGE>
REXALL SUNDOWN, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Dollars in thousands, except share and per share data)
7. Long-Term Debt and Borrowing Arrangements, continued
In March 1998, the Company entered into a revolving line of credit with a
financial institution with a borrowing amount of up to $30,000 which line of
credit is subject to annual extensions and compliance with certain financial
covenants and ratios. Borrowings under the line of credit bear interest at LIBOR
plus 1.0 percent. There were no amounts outstanding under this revolving line of
credit at August 31, 1998. The $30,000 line of credit replaced a $20,000 line of
credit that the Company entered into in December 1996, which had a stated
interest rate of LIBOR plus 1.5 percent. There were no amounts outstanding under
the $20,000 revolving line of credit at August 31, 1997. During fiscal 1997,
Richardson maintained a revolving line of credit in an aggregate amount not to
exceed the lesser of $6,000 or an amount equal to 75% of eligible accounts
receivable plus 50% of eligible inventory. The line of credit, which had a
stated interest rate of U.S. Bank's prime lending rate plus .5 percent, was
subject to loan covenants and secured by Richardson's accounts receivable,
inventory and equipment. Subsequent to the Richardson transaction, the line of
credit was repaid in full.
8. Lease Obligations
The Company leases certain equipment, automobiles and warehouse and
distribution facilities under noncancelable operating leases. The leases provide
for monthly payments over terms of one to five years and certain of the leases
provide for renewal options. Total rent expense on all operating leases amounted
to approximately $2,250, $1,791 and $1,041 for the years ended August 31, 1998,
1997 and 1996, respectively.
The future minimum lease payments under noncancelable operating leases at
August 31, 1998 are as follows:
Fiscal Year
-----------
1999.............................................. $ 2,212
2000.............................................. 1,749
2001.............................................. 1,011
2002.............................................. 6
---------
Total...................................... $ 4,978
=========
9. Benefit Plans
The Company offers a 401(k) employee benefit plan (the "Plan"), which
provides for voluntary contributions by employees of up to 20% of their base
compensation (as defined in the Plan), subject to a maximum annual contribution.
The Company may, at the discretion of the Board of Directors, make a
contribution to the Plan. The Company contributed approximately $275, $252 and
$211 during fiscal 1998, 1997 and 1996, respectively.
In March 1993, the Board of Directors and shareholders adopted the
Company's 1993 Employee Stock Purchase Plan (the "1993 Stock Purchase Plan").
The 1993 Stock Purchase Plan enables participants to contribute cash in an
amount not to exceed 10% of salary per relevant pay period. Such funds are used
to periodically purchase shares of Common Stock for the account of each of the
participants in the 1993 Stock Purchase Plan at 90% of the market price of the
Common Stock. In August 1998, the Company amended and restated the 1993 Stock
Purchase Plan (the "Amended Stock Purchase Plan") to allow participants to
purchase shares of Common Stock at 85% of the market price of the Common Stock.
The Company has reserved 1,500,000 shares of Common Stock for issuance under the
Amended Stock Purchase Plan and may issue such shares or purchase additional
shares of Common Stock in the open market for participants. For the years ended
August 31, 1998 and 1997 participants purchased 5,383 and 7,102 shares in the
open market at an average purchase price of $26.91 and $14.44 per share,
respectively.
F-12
<PAGE>
REXALL SUNDOWN, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Dollars in thousands, except share and per share data)
9. Benefit Plans, continued
In February 1996, the Board of Directors adopted the Company's 1996
Rexall Showcase International Distributor Stock Purchase Plan (the "1996
Distributor Stock Purchase Plan"). The 1996 Distributor Stock Purchase Plan
enables participants to contribute cash in an amount not to exceed 20% of a
participant's monthly commission check. Such funds are used to periodically
purchase shares of Common Stock for the account of each of the participants in
the 1996 Distributor Stock Purchase Plan at either 95% or 100% of the market
price of the Common Stock, depending on a participant's level of achievement in
Rexall Showcase. The Company has reserved 1,000,000 shares of Common Stock for
issuance under the 1996 Distributor Stock Purchase Plan and may issue such
shares or purchase additional shares of Common Stock in the open market for
participants. For the years ended August 31, 1998 and 1997, participants
purchased 61,930 and 52,176 shares of Common Stock in the open market at an
average purchase price of $30.10 and $14.60 per share, respectively.
10. Common Stock Transactions
On September 28, 1998, the Company's Board of Directors authorized a
share repurchase program, which allows the Company to buy up to $100,000 of its
Common Stock. Under the terms of the program, which has no expiration date, the
Company may buy shares from time to time in the open market or in privately
negotiated transactions, depending on market conditions and other factors. As of
November 20, 1998, the Company has repurchased 3,470,000 shares pursuant to the
program.
On January 29, 1998, the Company exchanged 2,884,616 shares of the
Company's Common Stock for all of the common stock of Richardson. The
transaction was accounted for as a pooling of interests, and, accordingly, the
Company's historical financial statements have been restated to include the
financial position and results of operations of Richardson for all prior periods
presented. For further information regarding the Richardson transaction, see
Note 3.
On September 22, 1997, the Board of Directors declared a two-for-one
split of the Common Stock, which was effected in the form of a stock dividend.
The stock dividend was paid on October 23, 1997 to shareholders of record on
October 7, 1997.
On November 5, 1996, the Company consummated a public offering (the
"Offering") of 8,000,000 shares of Common Stock. Of those shares, 4,000,000 were
sold by the Company and 4,000,000 were sold by certain shareholders of the
Company. On December 3, 1996, the underwriters' over-allotment option to
purchase an additional 1,200,000 shares was exercised. Of those 1,200,000
shares, 800,000 were sold by the Company and 400,000 were sold by a shareholder
of the Company.
On March 14, 1996, the Board of Directors declared a three-for-two split
of the Common Stock, which was effected in the form of a stock dividend. The
stock dividend was paid on April 4, 1996 to shareholders of record on March 25,
1996.
All references to the number of shares of Common Stock, except shares
authorized, and to per share data in the consolidated financial statements have
been adjusted to reflect the stock splits on a retroactive basis.
11. Stock Options
In March 1993, the Board of Directors and shareholders adopted the
Company's 1993 Stock Incentive Plan (the "1993 Plan") for executives and other
key personnel. The 1993 Plan is administered by the Compensation/Stock Option
Committee of the Board of Directors of the Company. Under the 1993 Plan, all
options are to have an exercise price equal to the fair market value at the date
of grant. In September 1997, the Board of Directors amended the 1993 Plan to
increase the number of shares of Common Stock of the Company available
thereunder by 6,000,000 to a total of 15,000,000 shares, which amendment was
approved by the Company's shareholders in February 1998. Of the stock options
granted, substantially all are for a term of five to ten years. During fiscal
1998 and 1997, the Company realized a tax benefit through shareholders' equity
of $13,587 and $4,188, respectively, related to the exercise of stock options.
F-13
<PAGE>
REXALL SUNDOWN, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Dollars in thousands, except share and per share data)
11. Stock Options, continued
In March 1993, the Board of Directors and shareholders adopted the
Company's 1993 Non-Employee Director Stock Option Plan (the "1993 Director
Plan"). The maximum number of shares available for issuance under the 1993
Director Plan is 120,000 shares.
In July 1994, the Board of Directors adopted the Company's 1994
Non-Employee Director Stock Option Plan (the "1994 Director Plan"), which was
approved by the Company's shareholders in February 1995. The maximum number of
shares of Common Stock available for issuance under the 1994 Director Plan is
300,000 shares.
As of August 31, 1998, non-qualified stock options to purchase 1,855,800
shares of Common Stock had been granted outside of any Company plan and have an
exercise price equal to fair market value at date of grant. Substantially all of
these options are for a term of five to seven years.
In February 1996, the Board of Directors adopted the Company's Rexall
Showcase International Distributor Stock Option Plan (the "Distributor Plan").
The Distributor Plan provides for the granting of stock options to eligible
distributors upon attainment of specified conditions at an exercise price not
less than the fair market value on the date of grant. The maximum number of
shares of Common Stock available under the Distributor Plan is 1,000,000 shares.
Options granted under the Distributor Plan are for a term of four to five years.
Information with regard to the stock options is as follows:
<TABLE>
<CAPTION>
Shares
-------------------------------------------------------------------------
1993 Director Distributor Other Option Price
Plan Plans Plans Options Range
---------- ---------- ------------- --------- -------------
<S> <C> <C> <C>
Outstanding at August 31, 1995........ 4,844,850 75,000 - 1,719,300
Granted............................ 1,872,902 45,000 - 225,000 $4.75-$15.00
Cancelled.......................... (525,300) - - (292,500) $1.58-$7.25
Exercised.......................... (1,445,356) (2,000) - (1,040,800) $1.58-$5.71
---------- --------- ---------- ------------
Outstanding at August 31, 1996........ 4,747,096 118,000 - 611,000 $1.58-$15.00
Granted ........................... 1,718,500 90,000 181,600 - $11.88-$17.75
Cancelled.......................... (208,700) - - - $3.33-$13.25
Exercised.......................... (724,876) (2,000) - (413,000) $1.58-$6.31
---------- --------- ---------- ------------
Outstanding at August 31, 1997........ 5,532,020 206,000 181,600 198,000 $1.58-$17.75
Granted............................ 3,239,030 90,000 223,600 - $10.44-$38.04
Cancelled.......................... (555,923) (40,000) (1,080) - $2.71-$31.06
Exercised.......................... (1,775,219) (68,366) (8,240) (143,000) $1.58-$17.69
---------- --------- ---------- ------------
Outstanding at August 31, 1998........ 6,439,908 187,634 395,880 55,000
========== ========= ========== ============
Options currently exercisable......... 1,736,682 40,301 121,740 55,000
========== ========= ========== ============
Options available for grant at
August 31, 1998.................... 4,220,141 157,000 595,880 -
========== ========= ========== ============
</TABLE>
The weighted average fair value of options granted during the fiscal
year ended August 31, 1998 and 1997 was $16.26 and $14.30, respectively.
During fiscal 1996, Financial Accounting Standards Board issued SFAS
No. 123 "Accounting for Stock-Based Compensation". SFAS No. 123 encourages, but
does not require, the use of a fair value based method of accounting for
stock-based compensation plans under which the fair value of stock options is
determined on the date of grant and expensed over the vesting period of the
stock options. While the Company has elected to continue to apply the provisions
of APB 25, SFAS No. 123, requires pro forma disclosure of net income and income
per common share as if the fair value based method under SFAS No. 123 had been
adopted.
F-14
<PAGE>
REXALL SUNDOWN, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Dollars in thousands, except share and per share data)
11. Stock Options, continued
The pro forma net income and income per common share amounts below have
been derived using the Black-Scholes stock option pricing model with the
following assumptions for each stock option grant during the respective fiscal
year:
<TABLE>
<CAPTION>
Stock Options
Granted in Fiscal Year
-------------------- --------------------
1998 1997
-------------------- --------------------
<S> <C> <C>
Assumptions
Risk-free interest rate........................ 5.39%-6.88% 5.75%-6.63%
Expected life of stock options (years)......... 10 6
Expected volatility of common stock............ 55% 45%
Expected annual dividends on
common stock................................. -- --
</TABLE>
<TABLE>
<CAPTION>
1998 1997
-------------------- --------------------
<S> <C> <C>
Pro forma net income - as reported............... $69,234 $37,176
Pro forma net income - pro forma................. $57,604 $34,861
Pro forma net income per share - as reported..... $ 0.94 $ 0.53
Pro forma net income per share - pro forma....... $ 0.78 $ 0.49
</TABLE>
The pro forma effects on net income and income per common share for
fiscal 1998 and 1997 may not be representative of the pro forma effects SFAS
No. 123 may have in future years.
The following table summarizes information about stock options
outstanding at August 31, 1998:
<TABLE>
<CAPTION>
Options Outstanding Options Exercisable
---------------------------------------------------------------- ----------------------------------------
Weighted Average Weighted Number Weighted
Range of Number Remaining Average Exercisable Average
Exercise Price Outstanding Contractual Life Exercise Price at 8/31/98 Exercise Price
- -------------------- ----------------- ---------------------- ----------------- ------------------ ------------------
<S> <C> <C> <C> <C> <C>
$1.58 - $5.00 1,212,988 2.58 $ 3.29 965,156 $ 3.20
$5.01 - $10.00 1,017,390 7.16 $ 6.29 309,720 $ 6.31
$10.01 - $15.00 1,243,971 8.27 $12.06 310,107 $12.02
$15.01 - $20.00 1,759,213 8.50 $17.38 270,240 $17.43
$20.01 - $30.00 1,001,200 9.28 $25.00 45,000 $25.25
$30.01 - $38.04 843,660 8.11 $33.19 53,500 $35.25
</TABLE>
12. Sales to a Major Customer, Major Products and Concentration of Credit Risk
The Company had sales to a national retailer which represented
approximately 29% of net sales for the year ended August 31, 1998 and 17% for
the year ended August 31, 1997. Additionally, the Company had sales to an
affiliate of the national retailer which represented approximately 1% of net
sales for the year ended August 31, 1998.
The Company sells products to a large number of customers, which are
primarily in the United States. The Company continuously evaluates the credit
worthiness of each customer's financial condition and generally does not require
collateral.
F-15
<PAGE>
REXALL SUNDOWN, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Dollars in thousands, except share and per share data)
12. Sales to a Major Customer, Major Products and Concentration of Credit Risk,
continued
In the fourth quarter of fiscal 1997, the Company introduced an
exclusively licensed, patented product. For the year ended August 31, 1998, net
sales of this product were approximately 15% of the Company's net sales, which
includes sales to the national retailer discussed above.
Financial instruments that potentially subject the Company to
concentration of credit risk are cash, marketable securities and trade accounts
receivable. The Company places its temporary cash investments with high credit
quality financial institutions.
13. Income Taxes
The Company files a consolidated United States income tax return with its
domestic subsidiaries. For state income tax purposes, the Company and its
subsidiaries file on both a consolidated and separate return basis in the states
in which they do business. Rexall Showcase's foreign subsidiaries file income
tax returns in their respective countries of incorporation.
As discussed in Note 3, prior to January 1998, Richardson was an S
corporation for Federal income tax purposes and, accordingly, did not pay U.S.
Federal income taxes. Effective January 1998, Richardson was included in the
Company's U.S. Federal income tax return.
Deferred income taxes as of August 31, 1998 relate primarily to the
reserve for loss on disposition of discontinued operations which is deductible
when realized, stock compensation plan expenses, inventory and accounts
receivable reserves, book depreciation versus tax deprecation.
The following reflects the actual income tax provision (benefits) the
Company incurred for the fiscal years ended August 31, 1998, 1997 and 1996:
<TABLE>
<CAPTION>
Fiscal Year Ended August 31,
---------------------------------------------
1998 1997 1996
---------- -------- --------
<S> <C> <C> <C>
Current:
Federal.......................................... $36,880 $18,396 $ 8,871
State............................................ 3,278 1,625 776
Foreign.......................................... - - 60
---------- ----------- -----------
40,158 20,021 9,707
---------- ----------- -----------
Deferred:
Federal.......................................... (630) 176 1,921
State............................................ (55) - 153
Foreign.......................................... 605 (605) 17
---------- ----------- -----------
(80) (429) 2,091
---------- ----------- -----------
Total income tax provision....................... $40,078 $19,592 $11,798
========== =========== ===========
</TABLE>
F-16
<PAGE>
REXALL SUNDOWN, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Dollars in thousands, except share and per share data)
13. Income Taxes, continued
The following table summarizes the differences between the Company's
effective tax rate for financial statement purposes and the Federal statutory
rate as of August 31, 1998, 1997 and 1996:
<TABLE>
<CAPTION>
1998 1997 1996
-------- ------- ------
<S> <C> <C> <C>
Income tax provision, at 35%................................ $38,589 $20,322 $12,842
Subchapter S Corporation status of Richardson............... - (1,135) (1,610)
State income tax, net of federal benefit.................... 2,055 1,064 624
Tax exempt interest......................................... (987) (664) -
Non-deductible expenses..................................... (423) 128 83
Other, net.................................................. 844 (123) (141)
---------- ---------- ----------
Total income tax provision......................... $40,078 $19,592 $11,798
========== ========== ==========
</TABLE>
The significant components of the deferred tax assets and liabilities at
August 31, 1998, 1997 and 1996 are as follows:
<TABLE>
<CAPTION>
1998 1997 1996
-------- -------- --------
<S> <C> <C> <C>
Deferred income tax assets:
Loss on disposition of discontinued operations............ $ 185 $ 185 $ 185
Non-compete amortization ................................. - 39 149
Accounts receivable and other reserves.................... 503 67 66
Net operating losses...................................... - 605 -
Other ................................................... 723 89 102
-------- --------- --------
1,411 985 502
-------- --------- --------
Deferred income tax liabilities:
Depreciation.............................................. 944 598 527
Foreign................................................... - - 17
-------- --------- --------
944 598 544
-------- --------- --------
$ 467 $ 387 $ (42)
======== ========= ========
</TABLE>
As of August 31, 1998, the U.S. income tax return for year end August 31,
1995 was in the process of being examined by the Internal Revenue Service.
Management believes that the amounts provided for income taxes are adequate and
that ultimate resolution of the examination will result in no material impact on
the Company's consolidated results of operations or financial position.
14. Discontinued Operations
The net assets of the Company's remaining discontinued operations at
August 31, 1998 and 1997 were as follows:
<TABLE>
<CAPTION>
August 31,
----------------------------
1998 1997
---------- ---------
<S> <C> <C>
Property, plant and equipment, net (under
contract for sale)............................. $3,948 $3,948
Other net assets................................. 128 128
-------- --------
Total assets..................................... $4,076 $4,076
======== ========
</TABLE>
F-17
<PAGE>
REXALL SUNDOWN, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Dollars in thousands, except share and per share data)
14. Discontinued Operations, continued
On August 31, 1995, the Company's Board of Directors approved a plan to
divest Pennex Laboratories, Inc., now known as RSL Holdings, Inc. ("Pennex"), a
manufacturer of OTC pharmaceuticals. On November 17, 1995, Pennex ceased
operations and on February 1, 1996, substantially all the remaining assets of
Pennex were sold for $6,495. The Company received a $500 deposit and a
collateralized note for the balance. The terms of such note provide for interest
at 12%, payable monthly through March 1996. The rate of interest increased to
18% on April 1, 1996, although interest is being paid at 12% with the balance
accruing until the note is due in full. The note was assigned from Pennex to the
Company as partial consideration for amounts owed to the Company by Pennex. The
Company has been recording interest income on the 12% interest paid to the
Company.
As of August 5, 1998, the Company extended the maturity of the
collateralized note related to the sale of the assets of Pennex to August 31,
1999. Interest continues to accrue and is payable in accordance with the
previous terms. As of November 20, 1998, the purchaser is in default under the
terms of the most recent forbearance agreement with respect to payments due to
the Company and the Company is reviewing all its options with respect to such
forbearance agreement and collateralized note.
Assuming full collection of the balance of the collateralized note, as to
which no assurances can be given, the Company expects to record a reduction to
the estimated loss on disposition of approximately $1,400 (net of tax), or
approximately $.02 per share, which would be reflected as an adjustment to
discontinued operations.
15. Commitments and Contingencies
The Company was named in 27 lawsuits, of which 25 have been settled or
discontinued, relating to the manufacture of L-tryptophan. These lawsuits seek
or have sought compensation and damages for alleged personal injury from
ingestion of products containing allegedly contaminated L-tryptophan. The
Company does not consider losses resulting from the plaintiff's claims on the
two remaining lawsuits to be probable, and as such, no provision has been made
in the financial statements for any loss that may result to the Company as a
result of these actions. Additionally, in connection with the above mentioned
lawsuits, the Company has entered into an agreement with the apparent supplier
of all the alleged contaminated L-tryptophan products pursuant to which such
supplier has agreed to indemnify the Company against any judgment and to fund
settlements arising out of those claims in certain circumstances, as well as to
pay the legal fees and expenses of the defense. Based upon such indemnification
arrangements, the Company's product liability insurance and the product
liability insurance of the Company's supplier, the Company does not believe that
any adverse decision will have a material adverse effect on the Company.
Rexall Showcase has a policy that in the event of termination of the
relationship between Rexall Showcase and an independent distributor by
resignation, Rexall Showcase will repurchase from such distributor all
resaleable inventory purchased by such distributor within 12 months of such
termination, for 90% of the original net cost to the distributor.
The Company is also involved in litigation relating to claims arising out
of its operations in the normal course of business. The Company is not currently
engaged in any legal proceedings that are expected, individually or in the
aggregate, to have a material adverse effect on the Company.
In November 1998, several class action complaints alleging violations of
the federal securities laws were filed against the Company and certain officers
and directors of the Company. These suits purport to be on behalf of all persons
who purchased the Company's Common Stock between March 19, 1998 and November 5,
1998. Following initial review of the complaints which have been served, the
Company believes that the allegations are completely without merit, the lawsuits
are groundless, and the Company will vigorously defend against them, although no
assurance can be given that the Company will ultimately prevail in its defense.
F-18
<PAGE>
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT.
(a) Directors of the Company.
See the Company's Proxy Statement, incorporated by reference
in Part III of this Form 10-K, under the heading "Election of
Directors."
(b) Executive Officers of the Company.
See Part I of this Form 10-K at Page 14.
ITEM 11. EXECUTIVE COMPENSATION.
See the Company's Proxy Statement, incorporated by reference in Part
III of this Form 10-K, under the headings "Executive Compensation" and
"Certain Relationships and Related Transactions."
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.
See the Company's Proxy Statement, incorporated by reference in Part
III of this Form 10-K, under the heading "Security Ownership of Certain
Beneficial Owners and Management."
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.
See the Company's Proxy Statement, incorporated by reference in Part
III of this Form 10-K, under the heading "Certain Relationships and
Related Transactions."
25
<PAGE>
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K.
(a) Documents Filed as Part of this Report
--------------------------------------
(1) Financial Statements
See "Item 8. Financial Statements and Supplementary Data" for Financial
Statements included with this Annual Report on Form 10-K.
(2) Financial Statement Schedules
Schedule II - Valuation and Qualifying Accounts
All other schedules have been omitted because they are not required,
not applicable, or the information is otherwise set forth in the
financial statements or notes thereto.
(3) Exhibits
3.1 Amended and Restated Articles of Incorporation (1)
3.2 Amended and Restated By-Laws (1)
10.1 Amended and Restated Indemnification Agreement dated
March 15, 1993 between the Company and Showa Denko
America, Inc. (1)
10.2 Guaranty Agreement dated March 15, 1993 between the
Company and Showa Denko K.K. (1)
10.3 Amended and Restated 1993 Employee Stock Purchase
Plan (1)
10.4 Form of Non-Qualified Stock Option Agreement (1)
10.5 Amended and Restated 1993 Stock Incentive Plan (2)
10.6 Amended and Restated 1993 Non-Employee Director Stock
Option Plan (3)
10.7 Amended and Restated 1994 Non-Employee Director Stock
Option Plan (3)
10.8 1996 Rexall Showcase Distributor Stock Purchase Plan (4)
10.9 Rexall Showcase Distributor Stock Option Plan (5)
10.10 Employment Agreement dated April 1, 1995 between Carl
DeSantis and the Company, as amended on October 9, 1995
and on March 27, 1997 (6)
10.11 Employment Agreement dated April 1, 1995 between Damon
DeSantis and the Company, as amended on April 1, 1996
and on March 27, 1997 (6)
10.12 Employment Agreement dated April 1, 1995 between
Nickolas Palin and the Company, as amended on April 1,
1996, March 27, 1997 and September 1, 1998 (6)
26
<PAGE>
10.13 Employment Agreement dated April 1, 1995 between Geary
Cotton and the Company, as amended on March 27, 1997
(7)
10.14 Employment Agreement dated April 1, 1995 between Richard
Werber and the Company, as amended on March 27, 1997 (7)
10.15 Employment Agreement dated September 1, 1998 between
Christian Nast and the Company (11)
10.16 Employment Agreement dated September 8, 1998 between Ian
Stuart and the Company (11)
10.17 Business Loan Agreement dated December 13, 1996 between
the Company and Barnett Bank, NA (8)
10.18 Agreement dated December 29, 1995 by and between Pennex
Laboratories, Inc. (now known as RSL Holdings, Inc.)
and Oakmont Pharmaceuticals, Inc. (9)
10.19 Industrial Lease dated March 3, 1995 by and between WRC
Properties, Inc. (now known as Teachers Insurance and
Annuity Association of America) and Network Marketing,
L.C. (now known as Rexall Showcase International, Inc.)
(9)
10.20 Standard Industrial Lease dated May 16, 1996 between the
Company and Dermody Properties (9)
10.21 Purchase and Sale Agreement dated August 26, 1997 by and
between Levitz Furniture Corporation and the Company
(10)
10.22 Fifth Forbearance Agreement dated August 5, 1998 by and
between Oakmont Pharmaceuticals, Inc. and the Company
(11)
21 Subsidiaries of Registrant (11)
23 Consent of PricewaterhouseCoopers LLP (11)
27 Financial Data Schedule (for SEC use only) (11)
- --------------------
(1) Filed as an Exhibit to the Company's Registration Statement on
Form S-1 (File No. 33-61382) and incorporated herein by
reference.
(2) Filed as an Exhibit to the Company's Proxy Statement dated
December 29, 1997 and is incorporated herein by reference.
(3) Filed as an Exhibit to the Company's Proxy Statement dated
December 30, 1996 and is incorporated herein by reference.
(4) Filed as an Exhibit to the Company's Registration Statement on
Form S-3 (File No. 33-6571) and incorporated herein by
reference.
(5) Filed as an Exhibit to the Company's Registration Statement on
Form S-3 (File No. 33-7883) and incorporated herein by
reference.
27
<PAGE>
(6) The Employment Agreement is filed as an Exhibit to the
Company's Annual Report on Form 10-K for the Year Ended August
31, 1995, the April 1, 1996 amendment thereto is filed as an
Exhibit to the Company's Annual Report on Form 10-K for the
Year Ended August 31, 1996, and the March 27, 1997 amendment
thereto is filed as an Exhibit to the Company's Quarterly
Report on Form 10-Q for the Quarterly Period Ended May 31,
1997, each of which is incorporated herein by reference. The
September 1, 1998 amendment to Mr. Palin's Employment
Agreement is filed herewith.
(7) The Employment Agreement is filed as an Exhibit to the
Company's Annual Report on Form 10-K for the Year Ended August
31, 1995 and the March 27, 1997 amendment thereto is filed as
an Exhibit to the Company's Quarterly Report on Form 10-Q for
the Quarterly Period Ended May 31, 1997, each of which is
incorporated herein by reference.
(8) Filed as an Exhibit to the Company's Quarterly Report on Form
10-Q for the Quarterly Period Ended November 30, 1996 and is
incorporated herein by reference.
(9) Filed as an Exhibit to the Company's Annual Report on Form
10-K for the Year Ended August 31, 1996 and is incorporated
herein by reference.
(10) Filed as an Exhibit to the Company's Annual Report on Form
10-K for the Year Ended August 31, 1997 and is incorporated
herein by reference.
(11) Filed herewith.
(b) Reports on Form 8-K
-------------------
Form 8-K filed with the Securities and Exchange Commission on September
29, 1998 reporting under Item 5.
(c) Item 601 Exhibits
-----------------
The exhibits required by Item 601 of Regulation S-K are set forth in
(a)(3) above.
(d) Financial Statement Schedules
-----------------------------
The financial statement schedules required by Regulation S-K are set
forth in (a)(2) above.
28
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
REXALL SUNDOWN, INC.
Dated: November 24, 1998 By: /s/ Carl DeSantis
-----------------------
Carl DeSantis,
Chairman of the Board
Pursuant to the requirements of the Securities Exchange Act of 1934,
this report has been signed by the following persons in the capacities and on
the dates indicated.
<TABLE>
<CAPTION>
Signature Title Date
- --------- ----- ----
<S> <C> <C>
/s/ Carl DeSantis Chairman of the Board November 24, 1998
- ---------------------------
Carl DeSantis
/s/ Christian Nast Director and Chief November 24, 1998
- --------------------------- Executive Officer
Christian Nast
/s/ Damon DeSantis Director and President November 24, 1998
- ---------------------------
Damon DeSantis
/s/ Geary Cotton Vice President, Chief Financial; November 24, 1998
- --------------------------- Officer, Treasurer and Chief
Geary Cotton Accounting Officer
/s/ Nickolas Palin Director, Senior Executive Vice November 24, 1998
- --------------------------- President and President-
Nickolas Palin Sundown Vitamins
/s/ Dean DeSantis Director November 24, 1998
- ---------------------------
Dean DeSantis
/s/ Stanley Leedy Director November 24, 1998
- ---------------------------
Stanley Leedy
/s/ Melvin Stith Director November 24, 1998
- ---------------------------
Melvin Stith
</TABLE>
29
<PAGE>
<TABLE>
<CAPTION>
SCHEDULE II
REXALL SUNDOWN, INC.
VALUATION AND QUALIFYING ACCOUNTS
Balance at Charged to Charged to
Beginning Costs and Other Balance at
Description of Year Expenses Accounts Deductions End of Year
----------- --------------- --------------- --------------- --------------- ---------------
<S> <C> <C> <C> <C> <C>
Year ended August 31, 1998
Allowance for doubtful accounts $185,000 $350,000 $ - $ - $535,000
Year ended August 31, 1997
Allowance for doubtful accounts $185,000 $70,757 $ - $70,757 $185,000
Year ended August 31, 1996
Allowance for doubtful accounts $78,000 $219,990 $ - $112,990 $185,000
</TABLE>
September 1, 1998
Mr. Nickolas Palin
Rexall Sundown, Inc.
6111 Broken Sound Parkway, NW
Boca Raton, Florida 33487
Dear Nick:
Reference is hereby made to the Employment Agreement (the "Agreement") dated
April 1, 1995 between Rexall Sundown, Inc. (the "Company") and Nickolas Palin
(the "Employee"), as amended. Effective as of the date hereof, the Company and
the Employee have agreed to make the following amendments to the Agreement:
1. Section 2.1 of the Agreement is hereby amended by deleting Section
2.1 in its entirety and inserting the following provision in lieu thereof:
"2.1 Subject to the provisions of Article 5 below, the term of
this Agreement (the "Term") shall be a continuous four (4) year period
commencing on April 1, 1995 (the "Commencement Date") and continuing
such that on the Commencement Date and on each day thereafter prior to
a termination of employment, the Term shall automatically be extended
for one additional day such that upon a termination of employment of
Employee on any date during the Term, four (4) years shall then be
remaining in the Term. Not later than ninety (90) days prior to any
anniversary of the Commencement Date, either party may provide written
notice to the other of its intention not to extend the Term of this
Agreement beyond the four (4) years then remaining in the Term. Such
written notice shall be deemed proper notice to terminate this
Agreement at the end of the four (4) year Term then in effect."
2. Section 6.1(a) of the Agreement is hereby amended by deleting
Section 6.1(a) in its entirety and inserting the following provision in lieu
thereof:
"6.1 Certain Restrictions. The Employee covenants and
agrees with the Company as follows:
(a) He shall not at any time, directly or indirectly, for
himself or any other person, firm, corporation, partnership,
association or other entity which competes in any manner with the
Company or any of its subsidiaries or affiliates in the United States
of America, its territories or possessions, or any country in which the
Company or any of its subsidiaries or affiliates is doing business on
the date of termination of the Agreement (collectively, the
"Territory"), attempt to employ, employ or enter into any contractual
arrangement for employment with, any employee or former employee of the
Company or any of its subsidiaries or affiliates, unless such former
employee shall not have been employed by the Company or any of its
subsidiaries or affiliates for a period of at least two (2) years."
3. Section 6.1(b) of the Agreement is hereby amended by deleting
Section 6.1(b) in its entirety and inserting the following provision in lieu
thereof:
"(b) He shall not, during the term of this Agreement, and for
a period of three (3) years from and after the date of termination of
this Agreement, directly or indirectly, (i) acquire or own in any
manner any interest in, or loan any amount to, any person, firm,
partnership, corporation, association or other entity which competes in
any manner with the Company or any of its subsidiaries or affiliates in
the Territory, (ii) be employed by or serve as an employee, agent,
officer, director of, or as a consultant to, any person, firm,
partnership, corporation, association or other entity, other than the
Company and its subsidiaries and affiliates, which competes in any
manner with any of the Company or its subsidiaries or affiliates in the
Territory, or (iii) compete in any manner with the Company or its
subsidiaries or affiliates in the Territory. The foregoing provisions
of this Section 6.1(b) shall not prevent the Employee from acquiring or
owning not
<PAGE>
more than five percent (5%) of the equity securities of any entity
whose securities are listed for trading on a national securities
exchange or are regularly traded in the over-the-counter securities
market."
If the foregoing is in accordance with our understanding, please execute the
enclosed copy of this letter and return to the undersigned.
Very truly yours,
REXALL SUNDOWN, INC.
By: /s/ Damon DeSantis
-------------------------
Damon DeSantis, President
AGREED TO AND ACCEPTED
this 1st day of September 1998.
/s/ Nickolas Palin
- ---------------------
Nickolas Palin
EMPLOYMENT AGREEMENT
THIS EMPLOYMENT AGREEMENT ("Agreement") is entered into as of September
1, 1998 by and between REXALL SUNDOWN, INC., a Florida corporation (the
"Company"), and CHRISTIAN NAST (the "Employee").
R E C I T A L S
---------------
The Company desires to employ the Employee, and the Employee desires to
be employed by the Company, in accordance with the provisions contained in this
Agreement.
NOW, THEREFORE, in consideration of the premises and the respective
covenants and agreements of each of the Company and the Employee contained in
this Agreement, each of the Company and the Employee agrees as follows:
I. EMPLOYMENT
-------------
1.1 The Company employs the Employee and the Employee accepts such
employment. Subject to the direction of the Board of Directors of the Company,
the Employee shall serve as the Chief Executive Officer of the Company. The
Employee shall have such responsibilities, perform such duties and exercise such
power and authority as are inherent in, or incident to, the offices of Chief
Executive Officer. The Employee shall devote his full business time and
attention and his best efforts to the performance of his duties as an employee
of the Company.
1.2 During the Term, the Employee, if elected, shall serve as a
Director of the Company and/or a Director or officer of any subsidiary of the
Company without any additional compensation for such services other than the
compensation provided for hereunder.
II. TERM
--------
2.1 Subject to the provisions of Article 5 hereof, the term of this
Agreement shall be for a period of three (3) years commencing on September 1,
1998 and terminating on August 31, 2001 (the "Term").
III. COMPENSATION
-----------------
3.1 Salary. In payment for the obligations to be performed by the
Employee during the Term, the Company shall pay to the Employee (subject to any
applicable payroll and/or taxes required to be withheld) annual compensation
("Annual Compensation") equal to (i) a salary of Four Hundred Twenty Thousand
Dollars ($420,000) in cash for the year commencing September 1, 1998 and (ii)
for each succeeding year during the Term, a salary equal to that of the previous
year increased by the greater of (a) 5%, (b) the increase in the cost of living
based upon the Revised Consumer Price Index (1982-84=100) published by the
Bureau of Labor for Boca Raton, Florida utilizing September 1998 as the base
month, or (c) such increase as the Company's Board of Directors may determine in
excess of (a) and (b) above.
3.2 Payment of Salary. Payments of salary shall be made to the Employee
in installments from time to time on the same dates that payments of salary are
generally made to all senior management employees of the Company.
3.3 Incentive Compensation. The Company shall pay the Employee an
incentive compensation bonus in an amount up to one hundred percent (100%) of
Employee's Annual Compensation for each of the Company's fiscal years during the
Term hereof based upon such criteria as are mutually determined by the Company
and the Employee.
<PAGE>
IV. CERTAIN FRINGE BENEFITS
---------------------------
4.1 Generally. The Employee shall be entitled to reimbursement for
reasonable business expenses incurred in connection with his employment
including customer entertainment. The Company shall provide the Employee with an
automobile allowance or an automobile of the type currently provided to senior
executives of the Company at the Company's expense and the Company shall provide
at its expense insurance, gas and maintenance for such automobile. The Company
will also provide you with a car or cellular telephone and a company credit card
for business travel and entertainment. The Employee shall further be entitled to
receive such benefits and to participate in such benefit plans as are generally
provided from time to time by the Company to its senior management employees;
provided, however, that nothing contained in this Section 4.1 shall be construed
to obligate the Company to provide any specific benefits to its employees
generally.
4.2 Vacations. The Employee shall be entitled to such vacation time on
an annual basis as is provided in accordance with the policies as are from time
to time in force for the Company's employees.
V. TERMINATION OF EMPLOYMENT
----------------------------
5.1 Certain Definitions. The following terms shall have the following
respective meanings when utilized in this Agreement:
(a) "Acquisition of Control" shall mean:
(i) any person (including a Group), without the
approval of a majority of the Incumbent Directors, becoming
the Beneficial Owner of, or acquiring the power to direct the
exercise of voting power with respect to, directly or
indirectly, securities which represent thirty percent (30%) or
more of the combined voting power of the Company's outstanding
securities thereafter, whether or not some portion of such
securities was owned by such person (or by any member of such
Group) prior thereto; provided, however, that this provision
shall not apply to acquisitions by a director, executive
officer or their affiliates if such person had such status on
April 24, 1995; or
(ii) the Incumbent Directors cease at any time to
constitute a majority of the Board of Directors, whether of
(A) the Company or (B) after any cash tender offer or exchange
offer, merger, consolidation or other business combination,
recapitalization of the Company, sale, liquidation or
dissolution (or adoption of a plan for liquidation or
dissolution), or any combination of any or all of the
foregoing transactions, including but not limited to a series
of such transactions, any successor to the Company; provided,
however, an Acquisition of Control shall not be deemed to have
occurred with respect to the Employee if the action of the
Employee was voluntary and would have been sufficient, without
the action of others, to constitute an Acquisition of Control.
(b) "Beneficial Owner" shall have the meaning provided in
Section 607.0901(1)(e) of the Florida Statutes.
(c) "Cause" shall mean any action by the Employee or any
inaction by the Employee which is reasonably believed by the Company to
constitute:
(i) fraud, embezzlement, misappropriation,
dishonesty or breach of trust;
(ii) a felony or moral turpitude;
(iii) material breach or violation of any or all of
the covenants, agreements and obligations of the Employee set
forth in this Agreement, other than as the result of the
Employee's death or Disability;
(iv) a willful or knowing failure or refusal by the
Employee to perform any or all of his material duties and
responsibilities as an officer of the Company, other than as
the result of the Employee's death or Disability; or
<PAGE>
(v) gross negligence by the Employee in the
performance of any or all of his material duties and
responsibilities as an officer of the Company, other than as
the result of the Employee's death or Disability; provided,
however, that if the basis for any termination of the
Employee's employment by the Company as set forth in the
Termination Notice delivered by the Company to the Employee is
any or all of the definitions of Cause set forth in Section
5.1(c)(iii) or Section 5.1.(c)(iv) of this Agreement, then, in
such event, the Employee shall have thirty (30) days from and
after the date of his receipt of such Termination Notice to
cure the action or inaction specified therein to the
reasonable satisfaction of the Company.
(d) "Compensation" shall mean the cash payment to which
Employee is entitled under the provisions of Sections 3.1 and 3.3
hereof.
(e) "Disability" shall mean any mental or physical illness,
condition, disability or incapacity which prevents the Employee from
reasonably discharging his duties and responsibilities as an officer of
the Company. If any disagreement or dispute shall arise between the
Company and the Employee as to whether the Employee suffers from any
Disability, then, in any such event, the Employee shall submit to the
physical or mental examination of a physician licensed under the laws
of the State of Florida, who shall be mutually selected by the Company
and the Employee, and such physician shall make the determination of
whether the Employee suffers from any Disability. In the absence of
fraud or bad faith, the determination of such physician shall be final
and binding upon each of the Company and the Employee. The entire cost
of any such examination shall be borne solely by the Employee.
(f) "Group" shall mean any combination of persons knowingly
participating in a joint activity or interdependent consciously
parallel action toward a common goal, whether or not pursuant to an
express contract; provided, however, that actions taken by a director
of the Company acting as such shall not alone constitute membership in
a Group.
(g) "Incumbent Director" shall mean any director of the
Company serving at April 24, 1995 or one elected thereafter if
nominated or approved by at least two-thirds of the then Incumbent
Directors.
(h) "Protracted Disability" shall mean any Disability which
prevents the Employee from reasonably discharging his duties and
responsibilities as an officer of the Company for a period of six (6)
consecutive months.
(i) "Termination Date" shall mean a specific date not less
than ten (10) nor more than thirty (30) days from and after the date of
any Termination Notice upon which the Employee's employment by the
Company shall be terminated in accordance with the provisions of this
Agreement.
(j) "Termination Notice" shall mean a written notice which (i)
sets forth the specific provision of this Agreement relied upon to
terminate the Employee's employment by the Company, (ii) sets forth in
reasonable detail the facts and circumstances claimed to provide the
basis for the termination of the Employee's employment by the Company
pursuant to the specific provision of this Agreement relied upon
therein and (iii) sets forth a Termination Date.
5.2 Termination of Employment.
(a) Notwithstanding the provisions of Article 2 hereof, this
Agreement (i) shall be automatically terminated upon the death of the
Employee pursuant to the provisions of Section 5.3 hereof and (ii) may
be terminated at any time by the Company pursuant to the provisions of
Section 5.4 or 5.5 hereof.
(b) If either the Company or the Employee shall desire to
terminate the Employee's employment by the Company pursuant to any of
the provisions of Sections 5.4 or 5.5 hereof, then the party causing
any such termination shall give to the other party a Termination
Notice.
(c) If this Agreement shall be terminated pursuant to any of
the provisions of this Article 5, the Company shall be discharged from
all of its obligations to the Employee hereunder upon its payment to
the
<PAGE>
Employee of the required amount set forth in the section of
this Article 5 pursuant to which such termination shall occur.
5.3 Death of Employee. If at any time during the Term the Employee
shall die, then the employment of the Employee by the Company shall
automatically terminate on the date of the Employee's death. In such event, not
more than thirty (30) days from and after the date of the Employee's death, the
Company shall pay to the Employee's estate or heirs, as the case may be, an
amount in cash equal to the Employee's Compensation (subject to any applicable
payroll and/or other taxes required by law to be withheld) determined as of the
date of the Employee's death.
5.4 Disability of Employee.
(a) If at any time during the Term the Employee shall suffer
any Disability, then the Company shall be obligated to continue to pay
in the ordinary and normal course of its business to the Employee or
his legal representatives, as the case may be, the Employee's
Compensation (subject to any applicable payroll and/or other taxes
required by law to be withheld) from the date that the Employee shall
first suffer any such Disability to the date that the Employee's
employment by the Company shall be terminated pursuant to any of the
provisions of this Agreement.
(b) If the Employee shall suffer any Protracted Disability
during the Term, then the Company may terminate this Agreement. In such
event, in addition to any other benefits which may have been provided
by the Company to the Employee or his legal representatives, as the
case may be, pursuant to the provisions of Section 5.4(a) hereof, not
later than thirty (30) days after the Termination Date specified in the
Termination Notice, the Company shall pay to the Employee or his legal
representatives, as the case may be, an amount in cash equal to the
Employee's Compensation (subject to any applicable payroll and/or other
taxes required by law to be withheld) determined as of the Termination
Date. Subsequent to such Termination Date, the Employee or his legal
representatives, as the case may be, shall also be entitled to receive
any benefits which may be payable under any disability insurance policy
or disability plan provided by the Company.
5.5 Termination of Employment by Company.
(a) The Company may terminate this Agreement at any time with
Cause. In such event, the Company shall be obligated to continue to pay
in the ordinary and normal course of its business to the Employee his
Annual Compensation (subject to any applicable payroll and/or other
taxes required by law to be withheld) until the Termination Date.
(b) The Company may terminate this Agreement at any time
without Cause. If the Company shall terminate the employment of the
Employee by the Company without Cause, and not pursuant to any other
provision of this Agreement, the Company shall continue to pay to the
Employee the Employee's Annual Compensation (subject to any applicable
payroll and/or other taxes required by law to be withheld) for a period
of one (1) year from the date of termination. If the Employee is
terminated without cause, the provisions of Section 6.1(b) hereof shall
be of no further force and effect.
5.6 Change in Control. Notwithstanding any other provisions of Sections
5.1 through 5.5 hereof, if (i) there is an Acquisition of Control and, (ii) at
any time within three (3) months prior to such Acquisition of Control or at any
time within one (1) year thereafter, either (A) the Employee for any reason
terminates his employment with the Company, or (B) the Employee's employment is
terminated without Cause, then the Employee shall have the option, but not the
obligation, of being paid in cash an amount equal to three (3) times his
Compensation for the then current fiscal year of the Company (amounts due under
this Section 5.6 are referred to as the "Payment"). If the Employee opts to
receive the Payment under this Section 5.6, whether his employment is terminated
by the Company or by himself, the provisions of Section 6.1(b) hereof shall be
of no further force or effect. Subject to the provisions of Section 5.7 hereof,
the Payment shall be made not later than three (3) months after the Employee
gives notice to the Company in the form of a Termination Notice of his election
under this Section 5.6.
5.7 Payments. Notwithstanding anything in the foregoing to the
contrary, if any of the payments provided for in this Agreement, together with
any other payments which the Employee has the right to receive from the Company,
would constitute a "parachute payment" (as defined in Section 280G(b)(2) of the
Internal Revenue
<PAGE>
Code), the payments pursuant to this Agreement shall be reduced to the largest
amount as will result in no portion of such payments being subject to the excise
tax imposed in Section 4999 of the Internal Revenue Code; provided, however,
that the Employee shall have the absolute discretion to direct the Company to
pay any amount which shall be payable to him pursuant to Section 5.6 hereof in
such equal annual installments as the Employee may direct, with the first such
installment payable when such amount would otherwise have been payable; and
further provided that the Employee shall have the absolute discretion to
allocate any reductions required by this Section 5.7 from amounts due him under
Section 5.6 hereof. The Company shall be obligated to comply with any directions
given to it by the Employee pursuant to the preceding sentence.
VI. CERTAIN RESTRICTIONS ON THE EMPLOYEE
----------------------------------------
6.1 Certain Restrictions. The Employee covenants and agrees with the
Company as follows:
(a) He shall not at any time, directly and indirectly, for
himself or any other person, firm, corporation, partnership,
association or other entity which competes in any manner with the
Company or any of its subsidiaries or affiliates in the United States
of America or its territories or possessions (collectively, the
"Territory"), attempt to employ, employ or enter into any contractual
arrangement for employment with, any employee or former employee of the
Company or any of its subsidiaries or affiliates, unless such former
employee shall not have been employed by the Company or any of its
subsidiaries or affiliates for a period of at least one year.
(b) He shall not, during the term of this Agreement, and for a
period of eighteen (18) months from and after the date of termination
of this Agreement, directly or indirectly, (i) acquire or own in any
manner any interest in, or loan any amount to, any person, firm,
partnership, corporation, association or other entity which competes in
any manner with the Company or any of its subsidiaries or affiliates in
the Territory, (ii) be employed by or serve as an employee, agent,
officer, director of, or as a consultant to, any person, firm,
partnership, corporation, association or other entity, other than the
Company and its subsidiaries and affiliates, which competes in any
manner with any of the Company or its subsidiaries or affiliates in the
Territory, or (iii) compete in any manner with the Company or its
subsidiaries or affiliates in the Territory. The foregoing provisions
of this Section 6.1(b) shall not prevent the Employee from acquiring or
owning not more than five percent (5%) of the equity securities of any
entity whose securities are listed for trading on a national securities
exchange or are regularly traded in the over-the-counter securities
market.
(c) He shall not at any time disclose, directly or indirectly,
to any person, firm, corporation, partnership, association or other
entity, any confidential information relating to the Company or any of
its subsidiaries or affiliates, including, without limitation, any
information concerning the financial condition, assets, personnel,
procedures, techniques, products, customers, sources of leads and
methods of obtaining new business or the methods generally of doing and
operating the respective businesses of the Company and its subsidiaries
and affiliates, trade secrets, product ideas, processes, techniques,
formulas, know-how, marketing plans and strategies, except to the
extent that such information is a matter of public knowledge or is
required to be disclosed by law or judicial or administrative process.
(d) He shall return all Company documents to the Company at
upon the termination of his employment by the Company.
6.2 Injunction. It is recognized and acknowledged by each of the
Company and the Employee that a breach or violation by the Employee of any or
all of his covenants and agreements contained in Section 6.1 hereof will cause
irreparable harm and damage to the Company and its subsidiaries and affiliates
in a monetary amount which would be virtually impossible to ascertain. As a
result, the Employee recognizes and acknowledges that the Company and its
subsidiaries and affiliates shall be entitled to a temporary restraining order
and/or injunction from any court of competent jurisdiction enjoining and
restraining any breach or violation by the Employee and/or his affiliates,
employees, associates, partners or agents, either directly or indirectly, of any
or all of the Employee's covenants and agreements contained in Section 6.1
hereof. Such right to a temporary restraining order and/or injunction shall be
cumulative and in addition to whatever other rights or remedies the Company and
its subsidiaries and affiliates may possess hereunder, at law or in equity.
Nothing contained in this Agreement shall be construed to prevent the Company
and its subsidiaries and affiliates from seeking and recovering from the
Employee damages suffered by any or all of them as a result of any breach or
violation by the Employee and/or his affiliates, employees, associates, partners
or agents of any or all of the Employee's covenants and agreements contained in
this Agreement.
<PAGE>
6.3 Reduction in Scope. In the event that any of the covenants and
agreements of the Employee contained in Section 6.1 hereof shall be held invalid
or unenforceable by a court of competent jurisdiction because of its duration or
geographic area, then, in any such event, such covenant or agreement shall be
reduced by such court in duration or geographical area or both to such extent as
to make it valid and enforceable in the jurisdiction where such court is
located, and in all other respects it shall remain in full force and effect.
VII. ATTORNEYS' FEES
--------------------
7.1 Prevailing Party. If any litigation shall arise between the Company
and the Employee based, in whole or in part, upon this Agreement or any or all
of the provisions contained herein, the prevailing party in any such litigation
shall be entitled to recover from the non-prevailing party, and shall be awarded
by a court of competent jurisdiction, any and all reasonable fees and
disbursements of trial and appellate counsel paid, incurred or suffered by such
prevailing party as the result of, arising from, or in connection with, any such
litigation.
VIII. MISCELLANEOUS
-------------------
8.1 Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of the State of Florida, without application of any
conflicts of laws principles. The Employee waives any plea of jurisdiction as
not being a resident of, or being located or conducting business in, Palm Beach
County, Florida and agrees that any litigation or action directly or indirectly
connected with this Agreement, shall, at the Company's election, be subject to
binding arbitration administered by the American Arbitration Association in West
Palm Beach, Florida.
8.2 Entire Agreement. This Agreement constitutes the entire agreement
between the Company and the Employee with respect to the subject matter hereof
and supersedes all prior negotiations, agreements, understandings and
arrangements, both oral and written, between the Company and the Employee with
respect to such subject matter. This Agreement may not be modified in any way,
except by a written instrument executed by each of the Company and the Employee.
8.3 Notices. Any and all notices required or permitted to be given
under this Agreement shall be in writing and shall be deemed to have been duly
given when delivered by hand, sent by a recognized overnight carrier such as
Federal Express or when deposited in the United States mail, by registered or
certified mail, return receipt requested, postage prepaid, as follows:
If to the Company: Rexall Sundown, Inc.
6111 Broken Sound Parkway, N.W.
Boca Raton, FL 33487
If to the Employee: Christian Nast
6111 Broken Sound Parkway, N.W.
Boca Raton, FL 33487
or to such other address as either party may from time to time give written
notice of to the other.
8.4 Benefits; Binding Effect. This Agreement shall be for the benefit
of, and shall be binding upon, each of the Company and the Employee and their
respective heirs, personal representatives, legal representatives, successors
and assigns.
8.5 Severability. The invalidity of any one or more of the words,
phrases, sentences, clauses or sections contained in this Agreement shall not
affect the enforceability of the remaining portions of this Agreement or any
part hereof, all of which are inserted conditionally on their being valid in
law. Except as is otherwise provided in Section 6.3 hereof, if any one or more
of the words, phrases, sentences, clauses or sections contained in this
Agreement shall be declared invalid by a court of competent jurisdiction, then,
in any such event, this Agreement shall be construed as if such invalid word or
words, phrase or phrases, sentence or sentences, clause or clauses, or section
or sections had not been inserted.
<PAGE>
8.6 Waivers. The waiver by either party of a breach or violation of any
term or provision of this Agreement by the other party shall not operate nor be
construed as a waiver of any subsequent breach or violation of any provision of
this Agreement nor of any other right or remedy.
8.7 Section Headings. The section headings contained in this Agreement
are for reference purposes only and shall not affect in any way the meaning or
interpretation of any or all of the provisions of this Agreement.
8.8 Counterparts. This Agreement may be executed in any number of
counterparts and by the separate parties hereto in separate counterparts, each
of which shall be deemed to constitute an original and all of which shall be
deemed to be the one and the same instrument.
IN WITNESS WHEREOF, each of the parties has executed and delivered this
Agreement as of the date first above written.
REXALL SUNDOWN, INC.
By: /s/ Carl DeSantis
-------------------------------------
Carl DeSantis, Chairman of the Board
/s/ Christian Nast
-------------------------------------
CHRISTIAN NAST
EMPLOYMENT AGREEMENT
THIS EMPLOYMENT AGREEMENT is entered into as of September 8, 1998 by
and between REXALL SUNDOWN, INC., a Florida corporation (the "Company"), and IAN
STUART the "Employee").
R E C I T A L S
---------------
The Company desires to employ the Employee, and the Employee desires to
be employed by the Company, in accordance with the provisions contained in this
Employment Agreement (the "Agreement").
NOW, THEREFORE, in consideration of the premises and the respective
covenants and agreements of each of the Company and the Employee contained in
this Agreement, each of the Company and the Employee agrees as follows:
I. EMPLOYMENT
-------------
1.1 The Company employs the Employee and the Employee accepts such
employment. Subject to the direction of the Board of Directors of the Company,
the Employee shall serve as the Executive Vice President and Chief Operating
Officer of the Company. The Employee shall have such responsibilities, perform
such duties and exercise such power and authority as are inherent in, or
incident to, the office of Executive Vice President and Chief Operating Officer.
The Employee shall devote his full business time and attention and his best
efforts to the performance of his duties as an employee of the Company.
II. TERM
2.1 Subject to the provisions of Article V hereof, the term of this
Agreement shall be for the period commencing on September 8, 1998, and
terminating on September 7, 2000 (the "Term").
III. COMPENSATION
3.1 Salary. In payment for the obligations to be performed by the
Employee during the Term, the Company shall pay to the Employee (subject to any
applicable payroll and/or taxes required to be withheld) annual compensation
("Annual Compensation") equal to (i) a salary of Three Hundred Thirty Thousand
Dollars ($330,000.00) in cash for the year ending September 7, 1999 and (ii) for
each succeeding year during the Term, a salary to be mutually agreed to by the
company and the Employer.
3.2 Payment of Salary. Payments of salary shall be made to the Employee
in installments from time to time on the same dates that payments of salary are
generally made to all employees of the Company.
3.3 Incentive Compensation. The Company shall pay the Employee
incentive compensation bonus in an amount up to sixty-two and one-half percent
(62.5%) of Employee's Annual Compensation for each of the Company's fiscal years
during the Term hereof based upon such criteria as are mutually determined by
the Company and the Employee.
IV. CERTAIN FRINGE BENEFITS
4.1 Generally. The Employee shall be entitled to reimbursement for
reasonable business expenses incurred in connection with his employment
including customer entertainment. The Company will also provide the Employee
with a credit card for business travel and entertainment and an automobile
allowance of $10,500 per annum. The Employee shall further be entitled to
receive such benefits and to participate in such benefit plans as are generally
provided from time to time by the Company to its employees; provided, however,
that nothing contained in this Section 4.1 shall be construed to obligate the
Company to provide any specific benefits to its employees generally.
<PAGE>
4.2 Vacations. The Employee shall be entitled to such vacation time on
an annual basis as is provided in accordance with the policies as are from time
to time in force for the Company's employees.
V. TERMINATION OF EMPLOYMENT
5.1 Certain Definitions. The following terms shall have the following
respective meanings when utilized in this Agreement:
(a) "Acquisition of Control" shall mean:
(i) any person (including a Group), without the
approval of a majority of the Incumbent Directors, becoming the Beneficial Owner
of, or acquiring the power to direct the exercise of voting power with respect
to, directly or indirectly, securities which represent thirty percent (30%) or
more of the combined voting power of the Company's outstanding securities
thereafter, whether or not some portion of such securities was owned by such
person (or by any member of such Group) prior thereto; provided, however, that
this provision shall not apply to acquisitions by a director, executive officer
or their affiliates if such person had such status on September 8, 1998; or
(ii) the Incumbent Directors cease at any time to
constitute a majority of the Board of Directors, whether of (A) the Company or
(B) after any cash tender offer or exchange offer, merger, consolidation or
other business combination, recapitalization of the Company, sale, liquidation
or dissolution (or adoption of a plan for liquidation or dissolution), or any
combination of any or all of the foregoing transactions, including but not
limited to a series of such transactions, any successor to the Company;
provided, however, an Acquisition of Control shall not be deemed to have
occurred with respect to the Employee if the action of the Employee was
voluntary and would have been sufficient, without the action of others, to
constitute an Acquisition of Control.
(b) "Beneficial Owner" shall have the meaning provided in
Section 607.0901(1)(e) of the Florida Statutes.
(c) "Cause" shall mean any action by the Employee or any
inaction by the Employee which is reasonably believed by the Company to
constitute:
(i) fraud, embezzlement, misappropriation, dishonesty
or breach of trust;
(ii) a felony or moral turpitude;
(iii) material breach or violation of any or all of
the covenants, agreements and obligations of the Employee set forth in this
Agreement, other than as the result of the Employee's death or Disability;
(iv) a willful or knowing failure or refusal by the
Employee to perform any or all of his material duties and responsibilities as an
officer of the Company, other than as the result of the Employee's death or
Disability; or
(v) gross negligence by the Employee in the
performance of any or all of his material duties and responsibilities as an
officer of the Company, other than as the result of the Employee's death or
Disability; provided, however, that if the basis for any termination of the
Employee's employment by the Company as set forth in the Termination Notice
delivered by the Company to the Employee is any or all of the definitions of
Cause set forth in Section 5.1(c)(iii) or Section 5.1(c)(iv) of this Agreement,
then, in such event, the Employee shall have thirty (30) days from and after the
date of his receipt of such Termination Notice to cure the action or inaction
specified therein to the reasonable satisfaction of the Company.
(d) "Compensation" shall mean the cash payment to which
Employee is entitled under the provisions of Sections 3.1 and 3.3 hereof.
(e) "Disability" shall mean any mental or physical illness,
condition, disability or incapacity which prevents the Employee from reasonably
discharging his duties and responsibilities as an officer of the Company. If any
disagreement or dispute shall arise between the Company and the Employee as to
whether the Employee suffers from any Disability, then, in any such event, the
Employee shall submit to the physical or mental
<PAGE>
examination of a physician licensed under the laws of the State of Florida, who
shall be mutually selected by the Company and the Employee, and such physician
shall make the determination of whether the Employee suffers from any
Disability. In the absence of fraud or bad faith, the determination of such
physician shall be final and binding upon each of the Company and the Employee.
The entire cost of any such examination shall be borne solely by the Employee.
(f) "Group" shall mean any combination of persons knowingly
participating in a joint activity or interdependent consciously parallel action
toward a common goal, whether or not pursuant to an express contract; provided,
however, that actions taken by a director of the Company acting as such shall
not alone constitute membership in a Group.
(g) "Incumbent Director" shall mean any director of the
Company serving at September 1, 1998 or one elected thereafter if nominated or
approved by at least two-thirds of the then Incumbent Directors.
(h) "Protracted Disability" shall mean any Disability which
prevents the Employee from reasonably discharging his duties and
responsibilities as an officer of the Company for a period of six (6)
consecutive months.
(i) "Termination Date" shall mean a specific date not less
than ten (10) nor more than thirty (30) days from and after the date of any
Termination Notice upon which the Employee's employment by the Company shall be
terminated in accordance with the provisions of this Agreement.
(j) "Termination Notice" shall mean a written notice which (i)
sets forth the specific provision of this Agreement relied upon to terminate the
Employee's employment by the Company, (ii) sets forth in reasonable detail the
facts and circumstances claimed to provide the basis for the termination of the
Employee's employment by the Company pursuant to the specific provision of this
Agreement relied upon therein and (iii) sets forth a Termination Date.
5.2 Termination of Employment.
(a) Notwithstanding the provisions of Article II hereof, this
Agreement (i) shall be automatically terminated upon the death of the Employee
pursuant to the provisions of Section 5.3 hereof, (ii) may be terminated at any
time by the Company pursuant to the provisions of Section 5.4 or 5.5 hereof and
(iii) may be terminated by the Employee pursuant to the provisions of Section
5.6 hereof.
(b) If either the Company or the Employee shall desire to
terminate the Employee's employment by the Company pursuant to any of the
provisions of Sections 5.4, 5.5 or 5.6 hereof, then the party causing any such
termination shall give to the other party a Termination Notice.
(c) If this Agreement shall be terminated pursuant to any of
the provisions of this Article V, the Company shall be discharged from all of
its obligations to the Employee hereunder upon its payment to the Employee of
the required amount set forth in the section of this Article 5 pursuant to which
such termination shall occur.
5.3 Death of Employee. If at any time during the Term the Employee
shall die, then the employment of the Employee by the Company shall
automatically terminate on the date of the Employee's death. In such event, not
more than thirty (30) days from and after the date of the Employee's death, the
Company shall pay to the Employee's estate or heirs, as the case may be, an
amount in cash equal to the Employee's Annual Compensation (subject to any
applicable payroll and/or other taxes required by law to be withheld) determined
as of the date of the Employee's death.
5.4 Disability of Employee.
(a) If at any time during the Term the Employee shall suffer
any Disability, then the Company shall be obligated to continue to pay in the
ordinary and normal course of its business to the Employee or his legal
representatives, as the case may be, the Employee's Annual Compensation (subject
to any applicable payroll and/or other taxes required by law to be withheld)
from the date that the Employee shall first suffer any such Disability to the
<PAGE>
date that the Employee's employment by the Company shall be terminated pursuant
to any of the provisions of this Agreement.
(b) If the Employee shall suffer any Protracted Disability
during the Term, then the Company may terminate this Agreement. In such event,
in addition to any other benefits which may have been provided by the Company to
the Employee or his legal representatives, as the case may be, pursuant to the
provisions of Section 5.4(a) hereof, not later than thirty (30) days after the
Termination Date specified in the Termination Notice, the Company shall pay to
the Employee or his legal representatives, as the case may be, an amount in cash
equal to the Employee's Annual Compensation (subject to any applicable payroll
and/or other taxes required by law to be withheld) determined as of the
Termination Date. Subsequent to such Termination Date, the Employee or his legal
representatives, as the case may be, shall also be entitled to receive any
benefits which may be payable under any disability insurance policy or
disability plan provided by the Company.
5.5 Termination of Employment by Company.
(a) The Company may terminate this Agreement at any time with
Cause. In such event, the Company shall be obligated to continue to pay in the
ordinary and normal course of its business to the Employee his Annual
Compensation (subject to any applicable payroll and/or other taxes required by
law to be withheld) until the Termination Date.
(b) The Company may terminate this Agreement at any time
without Cause. If the Company shall terminate the employment of the Employee by
the Company without Cause, and not pursuant to any other provision of this
Agreement, the Company shall continue to pay to the Employee the Employee's
Annual Compensation (subject to any applicable payroll and/or other taxes
required by law to be withheld) for a period of one (1) year from the date of
termination.
5.6 Change in Control. Notwithstanding any other provisions of Sections
5.1 through 5.5 hereof, if (i) there is an Acquisition of Control and, (ii) at
any time within three (3) months prior to such Acquisition of Control or at any
time within one (1) year thereafter, either (A) the Employee for any reason
terminates his employment with the Company, or (B) the Employee's employment is
terminated without Cause, then the Employee shall have the option, but not the
obligation, of being paid in cash an amount equal to two (2) times his
Compensation for the then current fiscal year of the Company (amounts due under
this Section 5.6 are referred to as the "Payment"). If the Employee opts to
receive the Payment under this Section 5.6, whether his employment is terminated
by the Company or by himself, the provisions of Section 6.1(b) hereof shall be
of no further force or effect. Subject to the provisions of Section 5.7 hereof,
the Payment shall be made not later than three (3) months after the Employee
gives notice to the Company in the form of a Termination Notice of his election
under this Section 5.6.
5.7 Payments. Notwithstanding anything in the foregoing to the
contrary, if any of the payments provided for in this Agreement, together with
any other payments which the Employee has the right to receive from the Company,
would constitute a "parachute payment" (as defined in Section 280G(b)(2) of the
Internal Revenue Code), the payments pursuant to this Agreement shall be reduced
to the largest amount as will result in no portion of such payments being
subject to the excise tax imposed in Section 4999 of the Internal Revenue Code;
provided, however, that the Employee shall have the absolute discretion to
direct the Company to pay any amount which shall be payable to him pursuant to
Section 5.6 hereof in such equal annual installments as the Employee may direct,
with the first such installment payable when such amount would otherwise have
been payable; and further provided that the Employee shall have the absolute
discretion to allocate any reductions required by this Section 5.7 from amounts
due him under Section 5.6 hereof. The Company shall be obligated to comply with
any directions given to it by the Employee pursuant to the preceding sentence.
VI. CERTAIN RESTRICTIONS ON THE EMPLOYEE
6.1 Certain Restrictions. The Employee covenants and agrees with the
Company as follows:
(a) He shall not at any time, directly and indirectly, for
himself or any other person, firm, corporation, partnership, association or
other entity which competes in any manner with the Company or any of its
subsidiaries or affiliates in the United States of America or its territories or
possessions (collectively, the "Territory"), attempt to employ, employ or enter
into any contractual arrangement for employment with, any employee or former
<PAGE>
employee of the Company or any of its subsidiaries or affiliates, unless such
former employee shall not have been employed by the Company or any of its
subsidiaries or affiliates for a period of at least one (1) year.
(b) He shall not, during the term of this Agreement, and for a
period of one (1) year from and after the date of termination of this Agreement,
directly or indirectly, (i) acquire or own in any manner any interest in, or
loan any amount to, any person, firm, partnership, corporation, association or
other entity which competes in any manner with the Company or any of its
subsidiaries or affiliates in the Territory, (ii) be employed by or serve as an
employee, agent, officer, director of, or as a consultant to, any person, firm,
partnership, corporation, association or other entity, other than the Company
and its subsidiaries and affiliates, which competes in any manner with any of
the Company or its subsidiaries or affiliates in the Territory, or (iii) compete
in any manner with the Company or its subsidiaries or affiliates in the
Territory. The foregoing provisions of this Section 6.1(b) shall not prevent the
Employee from acquiring or owning not more than five percent (5%) of the equity
securities of any entity whose securities are listed for trading on a national
securities exchange or are regularly traded in the over-the-counter securities
market.
(c) He shall not at any time disclose, directly or indirectly,
to any person, firm, corporation, partnership, association or other entity, any
confidential information relating to the Company or any of its subsidiaries or
affiliates, including, without limitation, any information concerning the
financial condition, assets, personnel, procedures, techniques, products,
customers, sources of leads and methods of obtaining new business or the methods
generally of doing and operating the respective businesses of the Company and
its subsidiaries and affiliates, trade secrets, product ideas, processes,
techniques, formulas, know-how, marketing plans and strategies, except to the
extent that such information is a matter of public knowledge or is required to
be disclosed by law or judicial or administrative process.
(d) He shall return all Company documents to the Company upon
the termination of his employment by the Company.
6.2 Injunction. It is recognized and acknowledged by each of the
Company and the Employee that a breach or violation by the Employee of any or
all of his covenants and agreements contained in Section 6.1 hereof will cause
irreparable harm and damage to the Company and its subsidiaries and affiliates
in a monetary amount which would be virtually impossible to ascertain. As a
result, the Employee recognizes and acknowledges that the Company and its
subsidiaries and affiliates shall be entitled to a temporary restraining order
and/or injunction from any court of competent jurisdiction enjoining and
restraining any breach or violation by the Employee and/or his affiliates,
employees, associates, partners or agents, either directly or indirectly, of any
or all of the Employee's covenants and agreements contained in Section 6.1
hereof. Such right to a temporary restraining order and/or injunction shall be
cumulative and in addition to whatever other rights or remedies the Company and
its subsidiaries and affiliates may possess hereunder, at law or in equity.
Nothing contained in this Agreement shall be construed to prevent the Company
and its subsidiaries and affiliates from seeking and recovering from the
Employee damages suffered by any or all of them as a result of any breach or
violation by the Employee and/or his affiliates, employees, associates, partners
or agents of any or all of the Employee's covenants and agreements contained in
this Agreement.
6.3 Reduction in Scope. In the event that any of the covenants and
agreements of the Employee contained in Section 6.1 hereof shall be held invalid
or unenforceable by a court of competent jurisdiction because of its duration or
geographic area, then, in any such event, such covenant or agreement shall be
reduced by such court in duration or geographical area or both to such extent as
to make it valid and enforceable in the jurisdiction where such court is
located, and in all other respects it shall remain in full force and effect.
VII. MISCELLANEOUS
7.1 Prevailing Party. If any litigation shall arise between the Company
and the Employee based, in whole or in part, upon this Agreement or any or all
of the provisions contained herein, the prevailing party in any such litigation
shall be entitled to recover from the non-prevailing party, and shall be awarded
by a court of competent jurisdiction, any and all reasonable fees and
disbursements of trial and appellate counsel paid, incurred or suffered by such
prevailing party as the result of, arising from, or in connection with, any such
litigation.
7.2 Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of the State of Florida, without application of any
conflicts of laws principles. The Employee waives any plea of jurisdiction as
not being a resident of, or being located or conducting business in, Palm Beach
County, Florida and
<PAGE>
agrees that any litigation or action directly or indirectly connected with this
Agreement, shall, at the Company's election, be subject to binding arbitration
administered by the American Arbitration Association in West Palm Beach,
Florida.
7.3 Entire Agreement. This Agreement constitutes the entire agreement
between the Company and the Employee with respect to the subject matter hereof
and supersedes all prior negotiations, agreements, understandings and
arrangements, both oral and written, between the Company and the Employee with
respect to such subject matter. This Agreement may not be modified in any way,
except by a written instrument executed by each of the Company and the Employee.
7.4 Notices. Any and all notices required or permitted to be given
under this Agreement shall be in writing and shall be deemed to have been duly
given when delivered by hand, sent by a recognized overnight carrier such as
Federal Express or when deposited in the United States mail, by registered or
certified mail, return receipt requested, postage prepaid, as follows:
If to the Company: Rexall Sundown, Inc.
6111 Broken Sound Parkway, N.W.
Boca Raton, FL 33487
Attn: Richard Werber,
Vice President and General Counsel
If to the Employee: Ian Stuart
6111 Broken Sound Parkway, N.W.
Boca Raton, FL 33487
or to such other address as either party may from time to time give written
notice of to the other.
7.5 Benefits; Binding Effect. This Agreement shall be for the benefit
of, and shall be binding upon, each of the Company and the Employee and their
respective heirs, personal representatives, legal representatives, successors
and assigns.
7.6 Severability. The invalidity of any one or more of the words,
phrases, sentences, clauses or sections contained in this Agreement shall not
affect the enforceability of the remaining portions of this Agreement or any
part hereof, all of which are inserted conditionally on their being valid in
law. Except as is otherwise provided in Section 6.3 hereof, if any one or more
of the words, phrases, sentences, clauses or sections contained in this
Agreement shall be declared invalid by a court of competent jurisdiction, then,
in any such event, this Agreement shall be construed as if such invalid word or
words, phrase or phrases, sentence or sentences, clause or clauses, or section
or sections had not been inserted.
7.7 Waivers. The waiver by either party of a breach or violation of any
term or provision of this Agreement by the other party shall not operate nor be
construed as a waiver of any subsequent breach or violation of any provision of
this Agreement nor of any other right or remedy.
7.8 Section Headings. The section headings contained in this Agreement
are for reference purposes only and shall not affect in any way the meaning or
interpretation of any or all of the provisions of this Agreement.
7.9 Counterparts. This Agreement may be executed in any number of
counterparts and by the separate parties hereto in separate counterparts, each
of which shall be deemed to constitute an original and all of which shall
<PAGE>
be deemed to be the one and the same instrument.
IN WITNESS WHEREOF, each of the parties has executed and delivered this
Agreement as of September 8, 1998.
REXALL SUNDOWN, INC.
By: /s/ Damon DeSantis
--------------------------
Damon DeSantis, President
/s/ Ian Stuart
--------------------------
Ian Stuart
FIFTH FORBEARANCE AGREEMENT
---------------------------
THIS FIFTH FORBEARANCE AGREEMENT (the "Fifth Forbearance Agreement") is
made as of August 5, 1998 by and between OAKMONT PHARMACEUTICALS, INC., a
Delaware corporation ("Oakmont"), and REXALL SUNDOWN, INC., a Florida
corporation ("Rexall Sundown"), as assignee of RSL Holdings, Inc. (formerly
known as Pennex Laboratories, Inc. and, before that, RS Acquisition, Inc.), a
Pennsylvania corporation ("RSL"), for the purpose of amending the payment terms
under the following agreements by and between Oakmont and Rexall Sundown: that
certain Forbearance Agreement dated April 29, 1996 (the "First Forbearance
Agreement"), that certain Second Forbearance Agreement dated September 23, 1996
(the "Second Forbearance Agreement"), that certain Third Forbearance Agreement
dated April 1, 1997 (the "Third Forbearance Agreement"), and that certain Fourth
Forbearance Agreement dated September 1, 1997 (the "Fourth Forbearance
Agreement").
Pursuant to an Agreement of Purchase and Sale dated as of December 29,
1995, by and between RSL as Seller and Oakmont as Buyer (the "Purchase
Agreement"), RSL sold to Oakmont various assets formerly used in RSL's
pharmaceutical manufacturing business (collectively, the "Assets"), including
(i) certain real estate in Plum Borough, Allegheny County, Pennsylvania (the
"Real Property"), wherein RSL conducted its pharmaceutical manufacturing
operations, and (ii) various items of personal property (collectively, the
"Personal Property") including equipment used by RSL in the conduct of its
operations conducted at the Real Property and inventory located at the Real
Property. RSL retained a mortgage lien on the Real Property and a security
interest in the Personal Property to secure Oakmont's payment of the unpaid
balance of the purchase price of the Assets and various other obligations owed
by Oakmont to RSL (collectively, the "Obligations") pursuant to a promissory
note dated January 31, 1996 (the "Note") and a mortgage dated February 1, 1996
and a security agreement dated January 31, 1996 (such mortgage and security
agreement are together hereinafter referred to as the "Security Documents").
Thereafter, RSL transferred all of its rights in respect of the Obligations and
in and under the Note and Security Documents to Rexall Sundown.
Oakmont defaulted in the timely payment of the Obligations. Thereafter,
Rexall Sundown and Oakmont entered into the First Forbearance Agreement, the
Second Forbearance Agreement, the Third Forbearance Agreement and the Fourth
Forbearance Agreement, whereby Rexall Sundown agreed to forbear from the
enforcement of its right to payment on the outstanding balance of the
Obligations on the terms and conditions set forth therein.
Simultaneously with the execution and delivery of the First Forbearance
Agreement, Oakmont delivered to Kirkpatrick & Lockhart LLP ("K&L"), counsel to
Rexall Sundown, at its office at 1500 Oliver Building, Pittsburgh, PA 15222, the
following items: (i) an executed and acknowledged Deed of Conveyance, conveying
the Real Property to a person or persons to be designated by Rexall Sundown; and
(ii) an executed Bill of Sale, conveying the Personal Property to a person or
persons to be designated by Rexall Sundown (the Deed and the Bill of Sale are
hereinafter collectively referred to as the "Transfer Documents"). K&L has been
holding the Transfer Documents in escrow pursuant to the terms of the First
Forbearance Agreement.
Oakmont has also defaulted in the timely payment of the amounts due
under the First Forbearance Agreement, the Second Forbearance Agreement, the
Third Forbearance Agreement and the Fourth Forbearance Agreement (the "Modified
Obligations"). Rexall Sundown is willing to forbear from the enforcement of its
rights and remedies in respect of such default, on the terms and conditions set
forth herein.
NOW THEREFORE, in consideration of the foregoing recitals and the
mutual promises herein contained, Oakmont and Rexall Sundown, each intending to
be legally bound, hereby, agree as follows:
1. Rexall Sundown waives any right to accelerate the maturity of the
outstanding balance of the Modified Obligations or to exercise any other right
or remedy under the Purchase Agreement, the Note, the Security Documents, or the
First Forbearance Agreement, the Second Forbearance Agreement, the Third
Forbearance or the Fourth Forbearance Agreement available by reason of any
payment default thereunder occurring prior to the date of this Fifth Forbearance
Agreement, and if such acceleration shall be deemed to have occurred prior to
the date hereof by reason of any such default, such acceleration shall be deemed
nullified and rescinded. Rexall Sundown further agrees not to accelerate the
maturity of the Modified Obligations or take any other action to enforce payment
of the
<PAGE>
Modified Obligations unless an Event of Default (as defined below in paragraph 5
below) shall have occurred and be continuing.
2. Oakmont will pay Rexall Sundown the following amounts and take the
following actions on or before the following dates:
(a) Wire transfer $250,000.00 to an account designated by Rexall
Sundown by no later than August 7, 1998;
(b) Wire transfer by no later than August 15, 1998 the sum of
$50,000.00 to the Plum Borough School District and the Borough of Plum,
Allegheny County, Pennsylvania (collectively, the "Borough") as part of an
installment payment program for the payment by Oakmont of delinquent real estate
taxes pursuant to an agreement between Oakmont and the Borough as evidenced by
the letter agreement dated July 24, 1998 between Frank W. Jones and Oakmont
attached hereto as Exhibit A;
(c) Provide evidence to Rexall Sundown by no later than August 7, 1998
that payment has been sent to the property and casualty carrier to bring the
insurance premiums current;
(d) Wire transfer an additional $250,000.00 to an account designated by
Rexall Sundown by no later than August 31, 1998;
(e) Commencing October 1, 1998 and on the first of each month
thereafter, wire transfer the sum of $60,000.00 per month to an account
designated by Rexall Sundown until the payments described in Section 2(f) and
(g) are made, and thereafter, wire transfer the sum of $50,000 per month until
all other amounts owing to Rexall Sundown are paid;
(f) Wire transfer the sum of $1,250,000 to an account designated by
Rexall Sundown upon the closing of a $5,000,000 taxable bond offering, but in no
event shall such payment be made later than October 30, 1998; and
(g) Wire transfer the sum of $2,000,000 to an account designated by
Rexall Sundown upon the closing of a $6,000,000 equity financing, but in no
event shall such payment be made later than November 30, 1998.
Payments made pursuant to Section 2(a), (d), (e), (f) and (g) shall be applied
first to accrued and unpaid interest on the Modified Obligations, and next to
the unpaid principal balance of the Modified Obligations. Payments made under
Section 2(e) hereof shall not reduce the amounts due under Sections 2(f) and
2(g) hereof.
3. On or before August 31, 1999, Oakmont shall pay Rexall Sundown the
outstanding balance due under the Purchase Agreement, the Note, and the Security
Documents as modified by the First Forbearance Agreement, the Second Forbearance
Agreement, the Third Forbearance Agreement, the Fourth Forbearance Agreement and
the Fifth Forbearance Agreement (collectively, the "Modified Documents"), as
specifically set forth on Exhibit B attached hereto.
4. Any of the following events shall constitute an "Event of Default"
for purposes of the Fifth Forbearance Agreement: (i) Any of the payments
required to be made pursuant to this Fifth Forbearance Agreement shall not be
made in full on or before its respective due date; or (ii) Oakmont shall have
defaulted in the payment or performance of any other duty or obligation under
the Modified Documents (other than any default waived by Rexall Sundown pursuant
to paragraph 1 above) and any applicable grace or cure period shall have
expired.
5. If any Event of Default shall have occurred and be continuing, then,
in any such event, Rexall Sundown may accelerate the maturity of all the
remaining amounts payable hereunder, and, in addition, may do any or all of the
following: (a) cause K&L to deliver the Transfer Documents to Rexall Sundown;
cause such Transfer Documents to be completed by the insertion of the name of
the transferee or transferees of the Real Property and the Personal Property;
and cause any or all of the Transfer Documents to be filed or recorded in the
appropriate public records; (b) cause judgment to be entered in favor of Rexall
Sundown (or its assignee) and against Oakmont for all or any part of the
outstanding balance of such amounts pursuant to the warrant of attorney
hereinafter set forth; and (c) exercise any and all other rights and remedies
provided by law.
<PAGE>
6. If, in accordance with this Fifth Forbearance Agreement, Rexall
Sundown elects to cause K&L to deliver to Rexall Sundown the Transfer Documents,
then Oakmont shall be released and discharged from any and all further liability
in respect of the amounts payable hereunder; provided, however, that nothing in
this Fifth Forbearance Agreement shall impair Rexall Sundown's right to enforce
its lien and security interest in the Assets.
7. If all the amounts payable to Rexall Sundown under the Modified
Documents are paid in full, then upon receipt of such payment, Rexall Sundown
shall release its lien and security interest in the Assets and shall cause K&L
to return the Transfer Documents to Oakmont.
8. This Fifth Forbearance Agreement may be executed in multiple
counterparts by different parties on different counterparts, each of which shall
be deemed an original, but all of which shall be deemed one and the same
instrument.
9. OAKMONT HEREBY AUTHORIZES ANY ATTORNEY OF ANY COURT IN THE
COMMONWEALTH OF PENNSYLVANIA TO APPEAR FOR OAKMONT AT ANY TIME AFTER THE
OCCURRENCE OF AN EVENT OF DEFAULT HEREUNDER, AND CONFESS A JUDGMENT OR JUDGMENTS
AGAINST OAKMONT AND IN FAVOR OF REXALL SUNDOWN OR ITS ASSIGNS, AS MANY TIMES AS
SHALL BE NECESSARY OR EXPEDIENT, FOR ALL OR ANY PART OF THE THEN OUTSTANDING
BALANCE DUE AND PAYABLE HEREUNDER, TOGETHER WITH AN ATTORNEY'S FEE OF 15% OF
SUCH AMOUNT, WITH RELEASE OF ALL ERRORS AND WITHOUT STAY OF EXECUTION.
IN WITNESS WHEREOF, we have hereunto set our hands and seals on or as
of the day and year first above written.
OAKMONT PHARMACEUTICALS, INC.
By: /s/ Arthur Michaels
-------------------------------
Name: Arthur Michaels
Title: Chief Executive Officer
REXALL SUNDOWN, INC.
By: /s/ Richard Werber
-------------------------------
Name: Richard Werber
Title: Vice President
Subsidiaries
------------
1. Rexall Showcase International, Inc.
2. Rexall Showcase International de Mexico, S.A. de C.V.
3. Importadora Rexall Showcase International de Mexico, S.A. de C.V.
4. Servicios Rexall Showcase International de Mexico, S.A. de C.V.
5. Asociacion de Vendedores Independientes en Rexall, A.C.
6. Rexall Korea Limited
7. RSL Holdings, Inc.
8. Rexall Hong Kong Limited
9. RXSD Inc.
10. Rexall Showcase Taiwan, Inc.
11. Rexall Showcase Japan, Inc.
12. Richardson Labs, Inc.
Consent of Independent Accountants
We consent to the incorporation by reference in the registration statements of
Rexall Sundown, Inc. on Form S-8 (Registration Statement Nos. 33-66282, 33-96906
and 333-34684) and on Form S-3 (Registration Statement Nos. 33-6571 and 33-7883)
of our report dated October 7, 1998, except for the fourth paragraph of Note 15
as to which date is November 24, 1998, on our audits of Rexall Sundown, Inc. as
of August 31, 1998 and 1997, and for the three years in the period ended August
31, 1998 appearing on page F-2 of this Form 10-K of Rexall Sundown, Inc. filed
with the Securities and Exchange Commission pursuant to the Securities Act of
1934.
/s/ PricewaterhouseCoopers LLP
- ------------------------------
PricewaterhouseCoopers LLP
Fort Lauderdale, Florida
November 30, 1998
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
For the twelve months ended August 31, 1998
(This schedule contains summary financial information extracted from Form 10-K
and is qualified in its entirety by reference to such financial statements).
</LEGEND>
<S> <C>
<PERIOD-TYPE> 12-MOS
<FISCAL-YEAR-END> Aug-31-1998
<PERIOD-END> Aug-31-1998
<CASH> 87,349,220
<SECURITIES> 32,045,300
<RECEIVABLES> 60,804,504<F1>
<ALLOWANCES> 0
<INVENTORY> 77,726,569
<CURRENT-ASSETS> 269,555,881
<PP&E> 56,697,411<F2>
<DEPRECIATION> 0
<TOTAL-ASSETS> 339,357,697
<CURRENT-LIABILITIES> 48,912,397
<BONDS> 0<F3>
0
0
<COMMON> 721,395
<OTHER-SE> 289,339,792
<TOTAL-LIABILITY-AND-EQUITY> 339,357,697
<SALES> 530,741,068
<TOTAL-REVENUES> 530,741,068
<CGS> 223,230,942
<TOTAL-COSTS> 223,230,942
<OTHER-EXPENSES> 201,655,313
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 218,637
<INCOME-PRETAX> 110,253,574
<INCOME-TAX> 40,077,947
<INCOME-CONTINUING> 70,175,627
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 70,175,627
<EPS-PRIMARY> 0.99
<EPS-DILUTED> 0.95
<FN>
F1 - Net of allowance.
F2 - Net of accumulated depreciation.
F3 - Includes Long-term obligations.
</FN>
</TABLE>
